drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.69k
| drug2_id
int64 0
1.69k
| drug_pair
sequencelengths 2
2
| drug1_name
stringlengths 4
85
| drug2_name
stringlengths 4
85
| drug1_desc
stringlengths 27
1.09k
| drug2_desc
stringlengths 27
6.14k
| label
stringclasses 3
values | label_idx
int64 0
2
| all_paths
sequencelengths 1
10
| all_paths_str
sequencelengths 1
10
| path_str
stringlengths 0
3.57k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00619 | DB11978 | 1,419 | 124 | [
"DDInter909",
"DDInter822"
] | Imatinib | Glasdegib | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.[A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined with low dose cytarabine. Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due to glasdegib's more favorable side effects profile. | Moderate | 1 | [
[
[
1419,
24,
124
]
],
[
[
1419,
25,
1135
],
[
1135,
23,
124
]
],
[
[
1419,
24,
466
],
[
466,
62,
124
]
],
[
[
1419,
24,
327
],
[
327,
24,
124
]
],
[
[
1419,
63,
475
],
[
475,
24,
124
]
],
[
[
1419,
25,
180
],
[
180,
63,
124
]
],
[
[
1419,
24,
829
],
[
829,
63,
124
]
],
[
[
1419,
25,
1670
],
[
1670,
24,
124
]
],
[
[
1419,
64,
1064
],
[
1064,
24,
124
]
],
[
[
1419,
23,
271
],
[
271,
24,
124
]
]
] | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glasdegib"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glasdegib"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
],
[
"Abametapir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
],
[
"Oliceridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
],
[
"Ubrogepant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
]
] | Imatinib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir and Abametapir may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Imatinib may lead to a major life threatening interaction when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant and Ubrogepant may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Imatinib may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Imatinib may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Imatinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib |
DB00553 | DB00850 | 92 | 1,630 | [
"DDInter1177",
"DDInter1432"
] | Methoxsalen | Perphenazine | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Moderate | 1 | [
[
[
92,
24,
1630
]
],
[
[
92,
63,
508
],
[
508,
40,
1630
]
],
[
[
92,
24,
1178
],
[
1178,
40,
1630
]
],
[
[
92,
6,
7950
],
[
7950,
45,
1630
]
],
[
[
92,
18,
3769
],
[
3769,
46,
1630
]
],
[
[
92,
18,
7359
],
[
7359,
57,
1630
]
],
[
[
92,
21,
29232
],
[
29232,
60,
1630
]
],
[
[
92,
63,
245
],
[
245,
24,
1630
]
],
[
[
92,
24,
1411
],
[
1411,
63,
1630
]
],
[
[
92,
24,
1419
],
[
1419,
24,
1630
]
]
] | [
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Methoxsalen",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Perphenazine"
]
],
[
[
"Methoxsalen",
"{u} (Compound) downregulates {v} (Gene)",
"EBP"
],
[
"EBP",
"{u} (Gene) is upregulated by {v} (Compound)",
"Perphenazine"
]
],
[
[
"Methoxsalen",
"{u} (Compound) downregulates {v} (Gene)",
"TXNDC9"
],
[
"TXNDC9",
"{u} (Gene) is downregulated by {v} (Compound)",
"Perphenazine"
]
],
[
[
"Methoxsalen",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Perphenazine"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
]
]
] | Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Perphenazine (Compound)
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Perphenazine (Compound)
Methoxsalen (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Perphenazine (Compound)
Methoxsalen (Compound) downregulates EBP (Gene) and EBP (Gene) is upregulated by Perphenazine (Compound)
Methoxsalen (Compound) downregulates TXNDC9 (Gene) and TXNDC9 (Gene) is downregulated by Perphenazine (Compound)
Methoxsalen (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Perphenazine (Compound)
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine |
DB01259 | DB12095 | 392 | 179 | [
"DDInter1024",
"DDInter1760"
] | Lapatinib | Telotristat ethyl | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding. | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ethyl is used to treat carcinoid syndrome diarrhea from neuroendocrine tumors that are inadequately controlled by short-acting somatostatin analog (SSA) treatment. Neuroendocrine cells are cells that secrete regulatory peptides and biogenic amines in response to chemical, neural, or other types of stimuli. Neuroendocrine tumors (NET) arising from these cells can therefore secrete chemical mediators into the bloodstream to cause side effects in distant sites, a phenomenon called carcinoid syndrome. The most common peptides and amines secreted by NET are histamines, tachykinins, kallikrein, and serotonin. Overexposure to serotonin can cause severe diarrhea, one of the main clinical symptoms of carcinoid syndrome. Serotonin is metabolized in the urinary metabolite 5-hydroxy indole acetic acid (u5-HIAA), and high levels of u5-HIAA is associated with poor survival outcome in patients with NET. The first line treatment of carcinoid syndrome diarrhea is SSA, but symptoms still reoccur over the course of the disease. | Moderate | 1 | [
[
[
392,
24,
179
]
],
[
[
392,
63,
79
],
[
79,
24,
179
]
],
[
[
392,
24,
310
],
[
310,
24,
179
]
],
[
[
392,
64,
1493
],
[
1493,
24,
179
]
],
[
[
392,
25,
1593
],
[
1593,
24,
179
]
],
[
[
392,
24,
283
],
[
283,
63,
179
]
],
[
[
392,
25,
877
],
[
877,
63,
179
]
],
[
[
392,
74,
883
],
[
883,
24,
179
]
],
[
[
392,
23,
1135
],
[
1135,
24,
179
]
],
[
[
392,
24,
1476
],
[
1476,
64,
179
]
]
] | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
],
[
"Halofantrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Lapatinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telotristat ethyl"
]
]
] | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Lapatinib may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Lapatinib may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Lapatinib may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Lapatinib (Compound) resembles Gefitinib (Compound) and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may lead to a major life threatening interaction when taken with Telotristat ethyl |
DB00635 | DB10675 | 1,573 | 961 | [
"DDInter1515",
"DDInter1065"
] | Prednisone | Licorice | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Licorice allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
1573,
24,
961
]
],
[
[
1573,
40,
870
],
[
870,
24,
961
]
],
[
[
1573,
1,
891
],
[
891,
24,
961
]
],
[
[
1573,
24,
1231
],
[
1231,
24,
961
]
],
[
[
1573,
63,
1214
],
[
1214,
24,
961
]
],
[
[
1573,
40,
870
],
[
870,
1,
891
],
[
891,
24,
961
]
],
[
[
1573,
1,
891
],
[
891,
40,
870
],
[
870,
24,
961
]
],
[
[
1573,
24,
1231
],
[
1231,
63,
870
],
[
870,
24,
961
]
],
[
[
1573,
40,
251
],
[
251,
40,
870
],
[
870,
24,
961
]
],
[
[
1573,
63,
1214
],
[
1214,
24,
870
],
[
870,
24,
961
]
]
] | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
],
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
],
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
],
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
],
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
],
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
]
] | Prednisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Prednisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Prednisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Prednisone (Compound) resembles Prednisolone (Compound) and Prednisolone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Prednisone (Compound) resembles Betamethasone (Compound) and Betamethasone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Licorice |
DB00986 | DB00999 | 1,192 | 504 | [
"DDInter834",
"DDInter883"
] | Glycopyrronium | Hydrochlorothiazide | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its indication as an adjunct therapy in the treatment of peptic ulcers.[A233570,L33090] Later research, taking advantage of the systemic distribution of muscarinic receptors through the body, found that glycopyrronium could also be used for reducing sweat gland, oral, airway, and gastric secretions; as well as reducing cardiac inhibitory reflexes; and reducing bronchoconstriction in COPD. Glycopyrronium is commonly prescribed as a first line treatment for a wide variety indications and is considered to have a wider therapeutic window than [tiotropium]. Glycopy | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors[L8390,L8423] or angiotensin II receptor blockers.[L7426,L7459] Hydrochlorothiazide was granted FDA approval on 12 February 1959. | Minor | 0 | [
[
[
1192,
23,
504
]
],
[
[
1192,
23,
178
],
[
178,
1,
504
]
],
[
[
1192,
62,
323
],
[
323,
40,
504
]
],
[
[
1192,
23,
674
],
[
674,
40,
504
]
],
[
[
1192,
18,
8386
],
[
8386,
57,
504
]
],
[
[
1192,
21,
29561
],
[
29561,
60,
504
]
],
[
[
1192,
63,
1442
],
[
1442,
23,
504
]
],
[
[
1192,
74,
352
],
[
352,
23,
504
]
],
[
[
1192,
24,
1511
],
[
1511,
62,
504
]
],
[
[
1192,
24,
1264
],
[
1264,
63,
504
]
]
] | [
[
[
"Glycopyrronium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Glycopyrronium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Polythiazide"
],
[
"Polythiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
]
],
[
[
"Glycopyrronium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
]
],
[
[
"Glycopyrronium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
]
],
[
[
"Glycopyrronium",
"{u} (Compound) downregulates {v} (Gene)",
"MTHFD2"
],
[
"MTHFD2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Hydrochlorothiazide"
]
],
[
[
"Glycopyrronium",
"{u} (Compound) causes {v} (Side Effect)",
"Mood swings"
],
[
"Mood swings",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydrochlorothiazide"
]
],
[
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
],
[
"Scopolamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Glycopyrronium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
]
]
] | Glycopyrronium may cause a minor interaction that can limit clinical effects when taken with Polythiazide and Polythiazide (Compound) resembles Hydrochlorothiazide (Compound)
Glycopyrronium may cause a minor interaction that can limit clinical effects when taken with Bendroflumethiazide and Bendroflumethiazide (Compound) resembles Hydrochlorothiazide (Compound)
Glycopyrronium may cause a minor interaction that can limit clinical effects when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Hydrochlorothiazide (Compound)
Glycopyrronium (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Hydrochlorothiazide (Compound)
Glycopyrronium (Compound) causes Mood swings (Side Effect) and Mood swings (Side Effect) is caused by Hydrochlorothiazide (Compound)
Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide
Glycopyrronium (Compound) resembles Trospium (Compound) and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide
Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide
Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide |
DB00196 | DB06402 | 600 | 1,079 | [
"DDInter743",
"DDInter1756"
] | Fluconazole | Telavancin | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose. | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others. | Moderate | 1 | [
[
[
600,
24,
1079
]
],
[
[
600,
21,
28680
],
[
28680,
60,
1079
]
],
[
[
600,
23,
112
],
[
112,
23,
1079
]
],
[
[
600,
24,
657
],
[
657,
63,
1079
]
],
[
[
600,
24,
543
],
[
543,
24,
1079
]
],
[
[
600,
25,
1181
],
[
1181,
24,
1079
]
],
[
[
600,
63,
521
],
[
521,
24,
1079
]
],
[
[
600,
25,
594
],
[
594,
63,
1079
]
],
[
[
600,
23,
609
],
[
609,
24,
1079
]
],
[
[
600,
25,
868
],
[
868,
64,
1079
]
]
] | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Fluconazole",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Telavancin"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Telavancin"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
],
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telavancin"
]
]
] | Fluconazole (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Telavancin (Compound)
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Telavancin
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Fluconazole may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Fluconazole may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Fluconazole may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Telavancin |
DB00407 | DB11703 | 202 | 405 | [
"DDInter115",
"DDInter9"
] | Ardeparin | Acalabrutinib | Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle cell lymphoma (MCL) who have already received at least one prior therapy. In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).[L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of acalabrutinib.[L10241,L42795] Also known as ACP-196, acalabrutinib is also considered a second generation BTK inhibitor because it was rationally designed to be more potent and selective than ibrutinib, theoretically expected to demonstrate fewer adverse effects owing to minimized bystander effects on targets other than BTK. Nevertheless, acalabrutinib was approved under the FDA's accelerated approval pathway, which is based upon overall response rate and faciliates earlier approval of medicines that treat serious conditions or/and that fill an unmet medical need based on a surrogate endpoint. Continued approval for acalabrutinib's currently accepted indication may subsequently be contingent upon ongoing verification and description of clinical benefit in confimatory trials. Furthermore, the FDA granted this medication Priority Review and Breakthrough Therapy designations. It also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. At this time, more than 35 clinical trials across 40 countries with more than 2500 patients are underway or have been completed with regards to further research into better understanding and expanding the therapeutic uses of acalabrutinib . | Major | 2 | [
[
[
202,
25,
405
]
],
[
[
202,
24,
557
],
[
557,
24,
405
]
],
[
[
202,
24,
738
],
[
738,
63,
405
]
],
[
[
202,
25,
126
],
[
126,
25,
405
]
],
[
[
202,
64,
1172
],
[
1172,
25,
405
]
],
[
[
202,
36,
553
],
[
553,
25,
405
]
],
[
[
202,
25,
283
],
[
283,
64,
405
]
],
[
[
202,
37,
1274
],
[
1274,
37,
405
]
],
[
[
202,
24,
557
],
[
557,
24,
1598
],
[
1598,
63,
405
]
],
[
[
202,
24,
121
],
[
121,
63,
1324
],
[
1324,
24,
405
]
]
] | [
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ardeparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
],
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ardeparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
],
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ardeparin",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
],
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ardeparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ardeparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
],
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
],
[
"Tazemetostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ardeparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
]
] | Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Ardeparin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Acalabrutinib
Ardeparin may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Acalabrutinib
Ardeparin (Compound) resembles Fondaparinux (Compound) and Ardeparin may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Acalabrutinib
Ardeparin may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Acalabrutinib
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Ardeparin may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib and Flurbiprofen may lead to a major life threatening interaction when taken with Acalabrutinib
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib |
DB00398 | DB01138 | 79 | 804 | [
"DDInter1702",
"DDInter1726"
] | Sorafenib | Sulfinpyrazone | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma. | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Moderate | 1 | [
[
[
79,
24,
804
]
],
[
[
79,
24,
998
],
[
998,
1,
804
]
],
[
[
79,
6,
3486
],
[
3486,
45,
804
]
],
[
[
79,
18,
7359
],
[
7359,
57,
804
]
],
[
[
79,
63,
1101
],
[
1101,
23,
804
]
],
[
[
79,
24,
629
],
[
629,
24,
804
]
],
[
[
79,
63,
1010
],
[
1010,
24,
804
]
],
[
[
79,
24,
1476
],
[
1476,
63,
804
]
],
[
[
79,
25,
11
],
[
11,
24,
804
]
],
[
[
79,
25,
1456
],
[
1456,
63,
804
]
]
] | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
[
"Phenylbutazone",
"{u} (Compound) resembles {v} (Compound)",
"Sulfinpyrazone"
]
],
[
[
"Sorafenib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Sulfinpyrazone"
]
],
[
[
"Sorafenib",
"{u} (Compound) downregulates {v} (Gene)",
"TXNDC9"
],
[
"TXNDC9",
"{u} (Gene) is downregulated by {v} (Compound)",
"Sulfinpyrazone"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
]
] | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Sulfinpyrazone (Compound)
Sorafenib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sulfinpyrazone (Compound)
Sorafenib (Compound) downregulates TXNDC9 (Gene) and TXNDC9 (Gene) is downregulated by Sulfinpyrazone (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Sulfinpyrazone
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone
Sorafenib may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone
Sorafenib may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone |
DB01200 | DB06691 | 469 | 849 | [
"DDInter243",
"DDInter1155"
] | Bromocriptine | Mepyramine | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptine has been associated with pulmonary fibrosis, and can also cause sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly. In 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological lactation after finding that bromocriptine was not shown to be safe for use.[L43942,L43947] It continues to be used for the indications mentioned above. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Moderate | 1 | [
[
[
469,
24,
849
]
],
[
[
469,
63,
1594
],
[
1594,
24,
849
]
],
[
[
469,
7,
2216
],
[
2216,
46,
849
]
],
[
[
469,
24,
407
],
[
407,
63,
849
]
],
[
[
469,
24,
830
],
[
830,
24,
849
]
],
[
[
469,
63,
662
],
[
662,
35,
849
]
],
[
[
469,
63,
1594
],
[
1594,
1,
11775
],
[
11775,
40,
849
]
],
[
[
469,
7,
2216
],
[
2216,
46,
499
],
[
499,
24,
849
]
],
[
[
469,
63,
770
],
[
770,
63,
1594
],
[
1594,
24,
849
]
],
[
[
469,
24,
407
],
[
407,
63,
1594
],
[
1594,
24,
849
]
]
] | [
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Bromocriptine",
"{u} (Compound) upregulates {v} (Gene)",
"PAK1"
],
[
"PAK1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Mepyramine"
]
],
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Chloropyramine"
],
[
"Chloropyramine",
"{u} (Compound) resembles {v} (Compound)",
"Mepyramine"
]
],
[
[
"Bromocriptine",
"{u} (Compound) upregulates {v} (Gene)",
"PAK1"
],
[
"PAK1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Phensuximide"
],
[
"Phensuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
]
] | Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Bromocriptine (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Mepyramine (Compound)
Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mepyramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Chloropyramine (Compound) and Chloropyramine (Compound) resembles Mepyramine (Compound)
Bromocriptine (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Phensuximide (Compound) and Phensuximide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine |
DB00317 | DB00357 | 883 | 1,051 | [
"DDInter810",
"DDInter71"
] | Gefitinib | Aminoglutethimide | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454) | Moderate | 1 | [
[
[
883,
24,
1051
]
],
[
[
883,
6,
8374
],
[
8374,
45,
1051
]
],
[
[
883,
21,
28803
],
[
28803,
60,
1051
]
],
[
[
883,
63,
1101
],
[
1101,
23,
1051
]
],
[
[
883,
24,
655
],
[
655,
63,
1051
]
],
[
[
883,
40,
1195
],
[
1195,
63,
1051
]
],
[
[
883,
1,
594
],
[
594,
63,
1051
]
],
[
[
883,
63,
215
],
[
215,
24,
1051
]
],
[
[
883,
35,
392
],
[
392,
63,
1051
]
],
[
[
883,
23,
479
],
[
479,
63,
1051
]
]
] | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
]
],
[
[
"Gefitinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Aminoglutethimide"
]
],
[
[
"Gefitinib",
"{u} (Compound) causes {v} (Side Effect)",
"Anaemia"
],
[
"Anaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aminoglutethimide"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aminoglutethimide"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
]
],
[
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Erlotinib"
],
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
]
],
[
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indinavir"
],
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
]
],
[
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
]
],
[
[
"Gefitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
]
]
] | Gefitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Aminoglutethimide (Compound)
Gefitinib (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Aminoglutethimide (Compound)
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide
Gefitinib (Compound) resembles Erlotinib (Compound) and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide
Gefitinib (Compound) resembles Bosutinib (Compound) and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Indinavir and Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide
Gefitinib (Compound) resembles Lapatinib (Compound) and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide
Gefitinib may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide |
DB00494 | DB01069 | 1,533 | 401 | [
"DDInter646",
"DDInter1533"
] | Entacapone | Promethazine | Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration of levodopa and a decarboxylase inhibitor. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] | Moderate | 1 | [
[
[
1533,
24,
401
]
],
[
[
1533,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1533,
24,
104
],
[
104,
24,
401
]
],
[
[
1533,
21,
28709
],
[
28709,
60,
401
]
],
[
[
1533,
40,
1062
],
[
1062,
24,
401
]
],
[
[
1533,
63,
701
],
[
701,
24,
401
]
],
[
[
1533,
25,
1053
],
[
1053,
63,
401
]
],
[
[
1533,
24,
1311
],
[
1311,
64,
401
]
],
[
[
1533,
24,
1264
],
[
1264,
63,
146
],
[
146,
24,
401
]
],
[
[
1533,
24,
820
],
[
820,
40,
11245
],
[
11245,
1,
401
]
]
] | [
[
[
"Entacapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Entacapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Entacapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Entacapone",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Promethazine"
]
],
[
[
"Entacapone",
"{u} (Compound) resembles {v} (Compound)",
"Tolcapone"
],
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Entacapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Entacapone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Entacapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
]
],
[
[
"Entacapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Entacapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Ethopropazine"
],
[
"Ethopropazine",
"{u} (Compound) resembles {v} (Compound)",
"Promethazine"
]
]
] | Entacapone may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Entacapone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Entacapone (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Promethazine (Compound)
Entacapone (Compound) resembles Tolcapone (Compound) and Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Entacapone may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Entacapone may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Entacapone may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may lead to a major life threatening interaction when taken with Promethazine
Entacapone may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Entacapone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Ethopropazine (Compound) and Ethopropazine (Compound) resembles Promethazine (Compound) |
DB01149 | DB09330 | 851 | 985 | [
"DDInter1274",
"DDInter1352"
] | Nefazodone | Osimertinib | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931] | Major | 2 | [
[
[
851,
25,
985
]
],
[
[
851,
63,
168
],
[
168,
23,
985
]
],
[
[
851,
25,
1478
],
[
1478,
24,
985
]
],
[
[
851,
64,
134
],
[
134,
24,
985
]
],
[
[
851,
24,
1040
],
[
1040,
24,
985
]
],
[
[
851,
63,
663
],
[
663,
24,
985
]
],
[
[
851,
25,
283
],
[
283,
63,
985
]
],
[
[
851,
24,
1383
],
[
1383,
63,
985
]
],
[
[
851,
1,
673
],
[
673,
24,
985
]
],
[
[
851,
62,
1101
],
[
1101,
24,
985
]
]
] | [
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
]
],
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Nefazodone",
"{u} (Compound) resembles {v} (Compound)",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Nefazodone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
]
] | Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Nefazodone may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Nefazodone may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Nefazodone may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Nefazodone (Compound) resembles Aripiprazole (Compound) and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Nefazodone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib |
DB01267 | DB11901 | 519 | 913 | [
"DDInter1381",
"DDInter107"
] | Paliperidone | Apalutamide | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749] | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors . In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or . Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines . Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which is the second-most common cause of cancer-related deaths in American males . Castration-resistant prostate cancer is often incurable, which poses significant clinical challenges for patients. Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis . Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death . In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment . In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo . Apalutamide displayed good tolerability and safety profile in clinical studies. Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant). It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer . | Moderate | 1 | [
[
[
519,
24,
913
]
],
[
[
519,
62,
112
],
[
112,
23,
913
]
],
[
[
519,
63,
600
],
[
600,
24,
913
]
],
[
[
519,
24,
28
],
[
28,
24,
913
]
],
[
[
519,
25,
877
],
[
877,
63,
913
]
],
[
[
519,
24,
1619
],
[
1619,
63,
913
]
],
[
[
519,
64,
475
],
[
475,
24,
913
]
],
[
[
519,
25,
1487
],
[
1487,
24,
913
]
],
[
[
519,
40,
1664
],
[
1664,
24,
913
]
],
[
[
519,
64,
593
],
[
593,
25,
913
]
]
] | [
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Paliperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Paliperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Paliperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Paliperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Paliperidone",
"{u} (Compound) resembles {v} (Compound)",
"Risperidone"
],
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Paliperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
]
] | Paliperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Paliperidone may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Paliperidone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Paliperidone may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Paliperidone (Compound) resembles Risperidone (Compound) and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Paliperidone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Apalutamide |
DB00281 | DB00754 | 608 | 157 | [
"DDInter1066",
"DDInter696"
] | Lidocaine | Ethotoin | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin is no longer commonly used. | Minor | 0 | [
[
[
608,
23,
157
]
],
[
[
608,
23,
759
],
[
759,
40,
157
]
],
[
[
608,
6,
11001
],
[
11001,
45,
157
]
],
[
[
608,
18,
15501
],
[
15501,
57,
157
]
],
[
[
608,
21,
28763
],
[
28763,
60,
157
]
],
[
[
608,
24,
384
],
[
384,
63,
157
]
],
[
[
608,
23,
1220
],
[
1220,
63,
157
]
],
[
[
608,
24,
1010
],
[
1010,
24,
157
]
],
[
[
608,
23,
1510
],
[
1510,
64,
157
]
],
[
[
608,
63,
600
],
[
600,
25,
157
]
]
] | [
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ethotoin"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Primidone"
],
[
"Primidone",
"{u} (Compound) resembles {v} (Compound)",
"Ethotoin"
]
],
[
[
"Lidocaine",
"{u} (Compound) binds {v} (Gene)",
"SCN10A"
],
[
"SCN10A",
"{u} (Gene) is bound by {v} (Compound)",
"Ethotoin"
]
],
[
[
"Lidocaine",
"{u} (Compound) downregulates {v} (Gene)",
"CCDC86"
],
[
"CCDC86",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ethotoin"
]
],
[
[
"Lidocaine",
"{u} (Compound) causes {v} (Side Effect)",
"Chest pain"
],
[
"Chest pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ethotoin"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ethotoin"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ethotoin"
]
]
] | Lidocaine may cause a minor interaction that can limit clinical effects when taken with Primidone and Primidone (Compound) resembles Ethotoin (Compound)
Lidocaine (Compound) binds SCN10A (Gene) and SCN10A (Gene) is bound by Ethotoin (Compound)
Lidocaine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Ethotoin (Compound)
Lidocaine (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Ethotoin (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Ethotoin
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ethotoin |
DB00060 | DB09061 | 912 | 1,627 | [
"DDInter947",
"DDInter284"
] | Interferon beta-1a | Cannabidiol | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investigated, CBD has shown promise as a therapeutic and pharmaceutical drug target. In particular, CBD has shown promise as an analgesic, anticonvulsant, muscle relaxant, anxiolytic, antipsychotic and has shown neuroprotective, anti-inflammatory, and antioxidant activity, among other currently investigated uses [A32477, A32469]. CBD's exact place within medical practice is still currently hotly debated, however as the body of evidence grows and legislation changes to reflect its wide-spread use, public and medical opinion have changed significantly with regards to its usefulness in a number of medical conditions ranging from anxiety to epilepsy. From a pharmacological perspective, Cannabis' (and CBD's) diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . Cannabinoid receptors are utilized endogenously by the body through the endocannabinoid system, which includes a group of lipid proteins, enzymes, and receptors that are involved in many physiological processes. Through its modulation of neurotransmitter release, the endocannabinoid system regulates cognition, pain sensation, appetite, memory, sleep, immune function, and mood among many other bodily systems. These effects are largely mediated through two members of the G-protein coupled receptor family, cannabinoid receptors 1 and 2 (CB1 and CB2)[A32585,A32824]. CB1 receptors are found in both the central and peripheral nervous systems, with the majority of receptors localized to the hippocampus and amygdala of the brain. Physiological effects of using cannabis make sense in the context of its receptor activity as the hippocampus and amygdala are primarily involved with regulation of memory, fear, and emotion. In contrast, CB2 receptors are mainly found peripherally in immune cells, lymphoid tissue, and peripheral nerve terminals . Tetrahydrocannabinol (THC) and cannabidiol (CBD) are two types of cannabinoids found naturally in the resin of the marijuana plant, both of which interact with the cannabinoid receptors that are found throughout the body. Although THC and CBD have been the most studied cannabinoids, there are many others identified to date including cannabinol (CBN), cannabigerol (CBG), (CBDV), and (THCV) that can be found within the medical cannabis . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms of THC like or ), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers. The primary psychoactive component of Cannabis, delta 9-tetrahydrocannabinol (Δ9-THC), demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors. This activity results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. In contrast to THC's weak agonist activity, CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body . Allosteric regulation is achieved through the modulation of receptor activity on a functionally distinct site from the agonist or antagonist binding site which is clinically significant as direct agonists (such as THC) are limited by their psychomimetic effects such as changes to mood, memory, and anxiety. In addition to the well-known activity on CB1 and CB2 receptors, there is further evidence that CBD also activates 5-HT1A/2A/3A serotonergic and TRPV1–2 vanilloid receptors, antagonizes alpha-1 adrenergic and µ-opioid receptors, inhibits synaptosomal uptake of noradrenaline, dopamine, serotonin and gamma-aminobutyric acid (GABA), and cellular uptake of anandamide, acts on mitochondria Ca2+ stores, blocks low-voltage-activated (T-type) Ca2+ channels, stimulates activity of the inhibitory glycine-receptor, and inhibits activity of fatty amide hydrolase (FAAH) [A31555, A31574]. CBD is currently available in Canada within a 1:1 formulation with tetrahydrocannbinol (THC) (as the formulation known as "nabiximols") as the brand name product Sativex. It is approved for use as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS). Sativex was also given a conditional Notice of Compliance (NOC/c) for use as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis and as adjunctive analgesic treatment for moderate to severe pain in adult patients with advanced cancer . In April 2018, a Food and Drug Administration advisory panel unanimously recommended approval of Epidiolex (cannabidiol oral solution) for the treatment of two rare forms of epilepsy - Lennox-Gastaut syndrome and Dravet syndrome, which are among the two most difficult types of epilepsy to treat [L2721, L2719]. Epidiolex was granted Orphan Drug designation as well as Fast Track Approval from the FDA for further study in these hard to treat conditions. Notably, phase 3 clinical trials of Epidiolex have demonstrated clinically significant improvement in Lennox-Gastaut syndrome and Dravet syndrome . On June 25th, 2018, Epidiolex was approved by the FDA to be the first CBD-based product available on the US market. | Moderate | 1 | [
[
[
912,
24,
1627
]
],
[
[
912,
24,
609
],
[
609,
23,
1627
]
],
[
[
912,
24,
351
],
[
351,
62,
1627
]
],
[
[
912,
24,
888
],
[
888,
24,
1627
]
],
[
[
912,
63,
1560
],
[
1560,
24,
1627
]
],
[
[
912,
24,
971
],
[
971,
63,
1627
]
],
[
[
912,
25,
1066
],
[
1066,
24,
1627
]
],
[
[
912,
25,
1510
],
[
1510,
25,
1627
]
],
[
[
912,
24,
609
],
[
609,
63,
723
],
[
723,
23,
1627
]
],
[
[
912,
24,
600
],
[
600,
24,
723
],
[
723,
23,
1627
]
]
] | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Interferon beta-1a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Interferon beta-1a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cannabidiol"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
]
]
] | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Interferon beta-1a may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Interferon beta-1a may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Cannabidiol
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Cannabidiol |
DB01191 | DB06700 | 1,039 | 643 | [
"DDInter518",
"DDInter511"
] | Dexfenfluramine | Desvenlafaxine | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).[L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. Although the exact mechanism of pathophysiology is still unknown, imbalances or deficiencies of monoamines have been heavily implicated, thus the rationale behind the use of SNRI to treat MDD. Desvenlafaxine has a very similar pharmacological, efficacy, and safety profile as [venlafaxine]. The major difference is the potential for drug interaction since venlafaxine is mainly metabolized by CYP2D6 while desvenlafaxine is conjugated by UGT; therefore, desvenlafaxine is less likely to cause drug-drug interaction when taken with medications affecting the CYP2D6 pathway. | Major | 2 | [
[
[
1039,
25,
643
]
],
[
[
1039,
64,
1100
],
[
1100,
1,
643
]
],
[
[
1039,
6,
6112
],
[
6112,
45,
643
]
],
[
[
1039,
24,
1383
],
[
1383,
63,
643
]
],
[
[
1039,
24,
1311
],
[
1311,
24,
643
]
],
[
[
1039,
63,
1274
],
[
1274,
24,
643
]
],
[
[
1039,
64,
506
],
[
506,
25,
643
]
],
[
[
1039,
25,
497
],
[
497,
25,
643
]
],
[
[
1039,
25,
1629
],
[
1629,
64,
643
]
],
[
[
1039,
64,
1100
],
[
1100,
40,
11228
],
[
11228,
1,
643
]
]
] | [
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} (Compound) resembles {v} (Compound)",
"Desvenlafaxine"
]
],
[
[
"Dexfenfluramine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A4"
],
[
"SLC6A4",
"{u} (Gene) is bound by {v} (Compound)",
"Desvenlafaxine"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} (Compound) resembles {v} (Compound)",
"Cyclopentolate"
],
[
"Cyclopentolate",
"{u} (Compound) resembles {v} (Compound)",
"Desvenlafaxine"
]
]
] | Dexfenfluramine may lead to a major life threatening interaction when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Dexfenfluramine (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Desvenlafaxine (Compound)
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Dexfenfluramine may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan may lead to a major life threatening interaction when taken with Desvenlafaxine
Dexfenfluramine may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Desvenlafaxine
Dexfenfluramine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Desvenlafaxine
Dexfenfluramine may lead to a major life threatening interaction when taken with Venlafaxine and Venlafaxine (Compound) resembles Cyclopentolate (Compound) and Cyclopentolate (Compound) resembles Desvenlafaxine (Compound) |
DB00719 | DB06282 | 1,219 | 516 | [
"DDInter149",
"DDInter1053"
] | Azatadine | Levocetirizine | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
1219,
24,
516
]
],
[
[
1219,
23,
771
],
[
771,
62,
516
]
],
[
[
1219,
24,
1074
],
[
1074,
63,
516
]
],
[
[
1219,
63,
701
],
[
701,
24,
516
]
],
[
[
1219,
24,
1178
],
[
1178,
24,
516
]
],
[
[
1219,
74,
21
],
[
21,
24,
516
]
],
[
[
1219,
25,
306
],
[
306,
24,
516
]
],
[
[
1219,
40,
830
],
[
830,
24,
516
]
],
[
[
1219,
23,
771
],
[
771,
62,
701
],
[
701,
24,
516
]
],
[
[
1219,
24,
1074
],
[
1074,
63,
701
],
[
701,
24,
516
]
]
] | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Azatadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levocetirizine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
],
[
"Iodide I-123",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Azatadine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Azatadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
],
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Azatadine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Azatadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
],
[
"Iodide I-123",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
]
] | Azatadine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and Iodide I-123 may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Azatadine (Compound) resembles Amitriptyline (Compound) and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Azatadine may lead to a major life threatening interaction when taken with Zonisamide and Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Azatadine (Compound) resembles Phenindamine (Compound) and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Azatadine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and Iodide I-123 may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine |
DB01138 | DB12267 | 804 | 1,476 | [
"DDInter1726",
"DDInter233"
] | Sulfinpyrazone | Brigatinib | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017. | Moderate | 1 | [
[
[
804,
24,
1476
]
],
[
[
804,
24,
1135
],
[
1135,
23,
1476
]
],
[
[
804,
62,
168
],
[
168,
23,
1476
]
],
[
[
804,
63,
629
],
[
629,
24,
1476
]
],
[
[
804,
24,
951
],
[
951,
24,
1476
]
],
[
[
804,
25,
1421
],
[
1421,
63,
1476
]
],
[
[
804,
25,
1618
],
[
1618,
24,
1476
]
],
[
[
804,
40,
998
],
[
998,
24,
1476
]
],
[
[
804,
24,
877
],
[
877,
63,
1476
]
],
[
[
804,
62,
1144
],
[
1144,
24,
1476
]
]
] | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brigatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brigatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} (Compound) resembles {v} (Compound)",
"Phenylbutazone"
],
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
]
] | Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Sulfinpyrazone may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Sulfinpyrazone may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Sulfinpyrazone may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Sulfinpyrazone (Compound) resembles Phenylbutazone (Compound) and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Sulfinpyrazone may cause a minor interaction that can limit clinical effects when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib |
DB01097 | DB01235 | 1,377 | 1,191 | [
"DDInter1033",
"DDInter1054"
] | Leflunomide | Levodopa | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after it has crossed the blood-brain barrier[Label,A177781]. Once past the blood-brain barrier, levodopa is metabolized to dopamine and supplements the low endogenous levels of dopamine to treat symptoms of Parkinson's[Label]. The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133]. | Moderate | 1 | [
[
[
1377,
24,
1191
]
],
[
[
1377,
64,
1307
],
[
1307,
40,
1191
]
],
[
[
1377,
64,
1551
],
[
1551,
1,
1191
]
],
[
[
1377,
21,
28936
],
[
28936,
60,
1191
]
],
[
[
1377,
64,
63
],
[
63,
24,
1191
]
],
[
[
1377,
24,
148
],
[
148,
63,
1191
]
],
[
[
1377,
63,
458
],
[
458,
24,
1191
]
],
[
[
1377,
25,
1510
],
[
1510,
63,
1191
]
],
[
[
1377,
25,
593
],
[
593,
24,
1191
]
],
[
[
1377,
25,
1053
],
[
1053,
25,
1191
]
]
] | [
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Melphalan"
],
[
"Melphalan",
"{u} (Compound) resembles {v} (Compound)",
"Levodopa"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methyldopa"
],
[
"Methyldopa",
"{u} (Compound) resembles {v} (Compound)",
"Levodopa"
]
],
[
[
"Leflunomide",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperhidrosis"
],
[
"Hyperhidrosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Levodopa"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teniposide"
],
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
],
[
"Secnidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinidazole"
],
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levodopa"
]
]
] | Leflunomide may lead to a major life threatening interaction when taken with Melphalan and Melphalan (Compound) resembles Levodopa (Compound)
Leflunomide may lead to a major life threatening interaction when taken with Methyldopa and Methyldopa (Compound) resembles Levodopa (Compound)
Leflunomide (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Levodopa (Compound)
Leflunomide may lead to a major life threatening interaction when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Levodopa
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Levodopa
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole and Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Levodopa
Leflunomide may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Levodopa
Leflunomide may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Levodopa
Leflunomide may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Levodopa |
DB00436 | DB00855 | 323 | 213 | [
"DDInter179",
"DDInter72"
] | Bendroflumethiazide | Aminolevulinic acid | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Major | 2 | [
[
[
323,
25,
213
]
],
[
[
323,
21,
28766
],
[
28766,
60,
213
]
],
[
[
323,
40,
1577
],
[
1577,
25,
213
]
],
[
[
323,
40,
504
],
[
504,
64,
213
]
],
[
[
323,
24,
848
],
[
848,
64,
213
]
],
[
[
323,
23,
1572
],
[
1572,
25,
213
]
],
[
[
323,
63,
245
],
[
245,
25,
213
]
],
[
[
323,
24,
92
],
[
92,
25,
213
]
],
[
[
323,
23,
1669
],
[
1669,
64,
213
]
],
[
[
323,
62,
964
],
[
964,
25,
213
]
]
] | [
[
[
"Bendroflumethiazide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aminolevulinic acid"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxsalen"
],
[
"Methoxsalen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Minocycline"
],
[
"Minocycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
]
] | Bendroflumethiazide (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Aminolevulinic acid (Compound)
Bendroflumethiazide (Compound) resembles Hydroflumethiazide (Compound) and Hydroflumethiazide may lead to a major life threatening interaction when taken with Aminolevulinic acid
Bendroflumethiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide may lead to a major life threatening interaction when taken with Aminolevulinic acid
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Aminolevulinic acid
Bendroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline may lead to a major life threatening interaction when taken with Aminolevulinic acid
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may lead to a major life threatening interaction when taken with Aminolevulinic acid
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen and Methoxsalen may lead to a major life threatening interaction when taken with Aminolevulinic acid
Bendroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Minocycline and Minocycline may lead to a major life threatening interaction when taken with Aminolevulinic acid
Bendroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline may lead to a major life threatening interaction when taken with Aminolevulinic acid |
DB00712 | DB12332 | 1,274 | 1,619 | [
"DDInter763",
"DDInter1626"
] | Flurbiprofen | Rucaparib | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
1274,
24,
1619
]
],
[
[
1274,
24,
222
],
[
222,
23,
1619
]
],
[
[
1274,
63,
84
],
[
84,
24,
1619
]
],
[
[
1274,
24,
1662
],
[
1662,
24,
1619
]
],
[
[
1274,
37,
1213
],
[
1213,
24,
1619
]
],
[
[
1274,
35,
848
],
[
848,
24,
1619
]
],
[
[
1274,
64,
663
],
[
663,
24,
1619
]
],
[
[
1274,
25,
4
],
[
4,
24,
1619
]
],
[
[
1274,
24,
1598
],
[
1598,
63,
1619
]
],
[
[
1274,
37,
503
],
[
503,
63,
1619
]
]
] | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nisoldipine"
],
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
],
[
"Tazemetostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
],
[
"Zanubrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
]
] | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Nisoldipine and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Flurbiprofen may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Flurbiprofen (Compound) resembles Ibuprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Flurbiprofen may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Flurbiprofen may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib and Flurbiprofen may lead to a major life threatening interaction when taken with Zanubrutinib and Zanubrutinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib |
DB00407 | DB05773 | 202 | 1,047 | [
"DDInter115",
"DDInter1848"
] | Ardeparin | Trastuzumab emtansine | Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000. | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity. | Major | 2 | [
[
[
202,
25,
1047
]
],
[
[
202,
25,
848
],
[
848,
24,
1047
]
],
[
[
202,
24,
222
],
[
222,
24,
1047
]
],
[
[
202,
63,
1560
],
[
1560,
24,
1047
]
],
[
[
202,
24,
738
],
[
738,
63,
1047
]
],
[
[
202,
64,
1061
],
[
1061,
24,
1047
]
],
[
[
202,
37,
1274
],
[
1274,
24,
1047
]
],
[
[
202,
25,
1439
],
[
1439,
63,
1047
]
],
[
[
202,
64,
1018
],
[
1018,
25,
1047
]
],
[
[
202,
25,
1409
],
[
1409,
64,
1047
]
]
] | [
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Ardeparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Ardeparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Ardeparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Ardeparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ipilimumab"
],
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
]
] | Ardeparin may lead to a major life threatening interaction when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Ardeparin may lead to a major life threatening interaction when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Ardeparin may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Ardeparin may lead to a major life threatening interaction when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Ardeparin may lead to a major life threatening interaction when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Trastuzumab emtansine
Ardeparin may lead to a major life threatening interaction when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Trastuzumab emtansine |
DB00444 | DB01174 | 63 | 697 | [
"DDInter1765",
"DDInter1442"
] | Teniposide | Phenobarbital | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle. | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
63,
24,
697
]
],
[
[
63,
24,
759
],
[
759,
1,
697
]
],
[
[
63,
63,
362
],
[
362,
1,
697
]
],
[
[
63,
6,
6017
],
[
6017,
45,
697
]
],
[
[
63,
21,
28741
],
[
28741,
60,
697
]
],
[
[
63,
24,
309
],
[
309,
63,
697
]
],
[
[
63,
25,
908
],
[
908,
63,
697
]
],
[
[
63,
63,
134
],
[
134,
24,
697
]
],
[
[
63,
64,
1057
],
[
1057,
24,
697
]
],
[
[
63,
35,
896
],
[
896,
24,
697
]
]
] | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
"Primidone",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
]
],
[
[
"Teniposide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Phenobarbital"
]
],
[
[
"Teniposide",
"{u} (Compound) causes {v} (Side Effect)",
"Agitation"
],
[
"Agitation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Phenobarbital"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Teniposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Teniposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Teniposide",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
]
] | Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenobarbital (Compound)
Teniposide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Phenobarbital (Compound)
Teniposide (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Phenobarbital (Compound)
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital
Teniposide may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital
Teniposide may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital
Teniposide (Compound) resembles Etoposide (Compound) and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital |
DB01030 | DB06176 | 869 | 1,342 | [
"DDInter1835",
"DDInter1616"
] | Topotecan | Romidepsin | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
869,
24,
1342
]
],
[
[
869,
23,
956
],
[
956,
24,
1342
]
],
[
[
869,
24,
1491
],
[
1491,
63,
1342
]
],
[
[
869,
63,
51
],
[
51,
24,
1342
]
],
[
[
869,
62,
739
],
[
739,
24,
1342
]
],
[
[
869,
24,
1213
],
[
1213,
24,
1342
]
],
[
[
869,
64,
1555
],
[
1555,
24,
1342
]
],
[
[
869,
25,
770
],
[
770,
24,
1342
]
],
[
[
869,
25,
962
],
[
962,
64,
1342
]
],
[
[
869,
64,
695
],
[
695,
25,
1342
]
]
] | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Topotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Topotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Topotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Topotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Topotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
],
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Topotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
]
] | Topotecan may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Topotecan may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Topotecan may lead to a major life threatening interaction when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Topotecan may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Topotecan may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen and Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Romidepsin
Topotecan may lead to a major life threatening interaction when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Romidepsin |
DB01225 | DB10344 | 500 | 992 | [
"DDInter645",
"DDInter818"
] | Enoxaparin | Ginger | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated [heparin], without increasing the risk of serious bleeding.[A228178,A228313] | Ginger allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
500,
24,
992
]
],
[
[
500,
64,
1578
],
[
1578,
24,
992
]
],
[
[
500,
25,
1421
],
[
1421,
63,
992
]
],
[
[
500,
25,
802
],
[
802,
24,
992
]
],
[
[
500,
64,
1578
],
[
1578,
25,
1421
],
[
1421,
63,
992
]
],
[
[
500,
25,
1421
],
[
1421,
64,
1578
],
[
1578,
24,
992
]
],
[
[
500,
64,
1167
],
[
1167,
64,
1578
],
[
1578,
24,
992
]
],
[
[
500,
64,
1479
],
[
1479,
63,
1578
],
[
1578,
24,
992
]
],
[
[
500,
25,
578
],
[
578,
63,
1578
],
[
1578,
24,
992
]
],
[
[
500,
23,
1631
],
[
1631,
62,
1578
],
[
1578,
24,
992
]
]
] | [
[
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
],
[
"Tinzaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Streptokinase"
],
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Enoxaparin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
]
] | Enoxaparin may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Enoxaparin may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Enoxaparin may lead to a major life threatening interaction when taken with Tinzaparin and Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Enoxaparin may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Enoxaparin may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Enoxaparin may lead to a major life threatening interaction when taken with Streptokinase and Streptokinase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Enoxaparin may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Enoxaparin may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Enoxaparin may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ginger |
DB00637 | DB12267 | 1,557 | 1,476 | [
"DDInter128",
"DDInter233"
] | Astemizole | Brigatinib | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017. | Moderate | 1 | [
[
[
1557,
24,
1476
]
],
[
[
1557,
24,
1612
],
[
1612,
23,
1476
]
],
[
[
1557,
24,
629
],
[
629,
24,
1476
]
],
[
[
1557,
63,
79
],
[
79,
24,
1476
]
],
[
[
1557,
24,
1598
],
[
1598,
63,
1476
]
],
[
[
1557,
25,
33
],
[
33,
24,
1476
]
],
[
[
1557,
40,
704
],
[
704,
24,
1476
]
],
[
[
1557,
64,
494
],
[
494,
24,
1476
]
],
[
[
1557,
25,
982
],
[
982,
63,
1476
]
],
[
[
1557,
25,
1091
],
[
1091,
25,
1476
]
]
] | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brigatinib"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
],
[
"Tazemetostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Astemizole",
"{u} (Compound) resembles {v} (Compound)",
"Fentanyl"
],
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
]
] | Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Astemizole may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Astemizole (Compound) resembles Fentanyl (Compound) and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Astemizole may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Astemizole may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Astemizole may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may lead to a major life threatening interaction when taken with Brigatinib |
DB12095 | DB12500 | 179 | 283 | [
"DDInter1760",
"DDInter714"
] | Telotristat ethyl | Fedratinib | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ethyl is used to treat carcinoid syndrome diarrhea from neuroendocrine tumors that are inadequately controlled by short-acting somatostatin analog (SSA) treatment. Neuroendocrine cells are cells that secrete regulatory peptides and biogenic amines in response to chemical, neural, or other types of stimuli. Neuroendocrine tumors (NET) arising from these cells can therefore secrete chemical mediators into the bloodstream to cause side effects in distant sites, a phenomenon called carcinoid syndrome. The most common peptides and amines secreted by | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
179,
24,
283
]
],
[
[
179,
24,
466
],
[
466,
62,
283
]
],
[
[
179,
63,
351
],
[
351,
23,
283
]
],
[
[
179,
63,
1419
],
[
1419,
24,
283
]
],
[
[
179,
24,
971
],
[
971,
24,
283
]
],
[
[
179,
24,
676
],
[
676,
63,
283
]
],
[
[
179,
64,
124
],
[
124,
24,
283
]
],
[
[
179,
63,
888
],
[
888,
25,
283
]
],
[
[
179,
25,
1017
],
[
1017,
25,
283
]
],
[
[
179,
64,
866
],
[
866,
25,
283
]
]
] | [
[
[
"Telotristat ethyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Telotristat ethyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Telotristat ethyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Telotristat ethyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Telotristat ethyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Telotristat ethyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Telotristat ethyl",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Telotristat ethyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Telotristat ethyl",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Telotristat ethyl",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
],
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
]
] | Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Telotristat ethyl may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Fedratinib
Telotristat ethyl may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Fedratinib
Telotristat ethyl may lead to a major life threatening interaction when taken with Cobimetinib and Cobimetinib may lead to a major life threatening interaction when taken with Fedratinib |
DB00227 | DB11718 | 1,463 | 927 | [
"DDInter1098",
"DDInter640"
] | Lovastatin | Encorafenib | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. | Moderate | 1 | [
[
[
1463,
24,
927
]
],
[
[
1463,
24,
112
],
[
112,
23,
927
]
],
[
[
1463,
24,
372
],
[
372,
24,
927
]
],
[
[
1463,
63,
1324
],
[
1324,
24,
927
]
],
[
[
1463,
24,
484
],
[
484,
63,
927
]
],
[
[
1463,
35,
467
],
[
467,
24,
927
]
],
[
[
1463,
25,
1510
],
[
1510,
24,
927
]
],
[
[
1463,
40,
681
],
[
681,
24,
927
]
],
[
[
1463,
24,
597
],
[
597,
25,
927
]
],
[
[
1463,
24,
1017
],
[
1017,
64,
927
]
]
] | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Encorafenib"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Lovastatin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Lovastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Lovastatin",
"{u} (Compound) resembles {v} (Compound)",
"Pravastatin"
],
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
]
] | Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Lovastatin (Compound) resembles Simvastatin (Compound) and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Lovastatin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Lovastatin (Compound) resembles Pravastatin (Compound) and Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may lead to a major life threatening interaction when taken with Encorafenib
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Encorafenib |
DB00549 | DB00773 | 522 | 896 | [
"DDInter1955",
"DDInter702"
] | Zafirlukast | Etoposide | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. | Moderate | 1 | [
[
[
522,
24,
896
]
],
[
[
522,
6,
3486
],
[
3486,
45,
896
]
],
[
[
522,
21,
28681
],
[
28681,
60,
896
]
],
[
[
522,
23,
307
],
[
307,
23,
896
]
],
[
[
522,
24,
147
],
[
147,
23,
896
]
],
[
[
522,
24,
700
],
[
700,
63,
896
]
],
[
[
522,
63,
322
],
[
322,
24,
896
]
],
[
[
522,
24,
1622
],
[
1622,
24,
896
]
],
[
[
522,
23,
807
],
[
807,
63,
896
]
],
[
[
522,
1,
165
],
[
165,
63,
896
]
]
] | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Etoposide"
]
],
[
[
"Zafirlukast",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Etoposide"
]
],
[
[
"Zafirlukast",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etoposide"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etoposide"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
],
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Zafirlukast",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ulipristal"
],
[
"Ulipristal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Zafirlukast",
"{u} (Compound) resembles {v} (Compound)",
"Tolvaptan"
],
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
]
] | Zafirlukast (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Etoposide (Compound)
Zafirlukast (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Etoposide (Compound)
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Etoposide
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Etoposide
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Ulipristal and Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Zafirlukast (Compound) resembles Tolvaptan (Compound) and Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Etoposide |
DB00346 | DB01259 | 472 | 392 | [
"DDInter44",
"DDInter1024"
] | Alfuzosin | Lapatinib | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding. | Moderate | 1 | [
[
[
472,
24,
392
]
],
[
[
472,
6,
8374
],
[
8374,
45,
392
]
],
[
[
472,
21,
29429
],
[
29429,
60,
392
]
],
[
[
472,
23,
112
],
[
112,
23,
392
]
],
[
[
472,
24,
918
],
[
918,
24,
392
]
],
[
[
472,
24,
603
],
[
603,
63,
392
]
],
[
[
472,
63,
618
],
[
618,
24,
392
]
],
[
[
472,
23,
752
],
[
752,
24,
392
]
],
[
[
472,
25,
877
],
[
877,
64,
392
]
],
[
[
472,
24,
1250
],
[
1250,
64,
392
]
]
] | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Alfuzosin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lapatinib"
]
],
[
[
"Alfuzosin",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation NOS"
],
[
"Infestation NOS",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lapatinib"
]
],
[
[
"Alfuzosin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lapatinib"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abarelix"
],
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Alfuzosin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Alfuzosin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
]
]
] | Alfuzosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Alfuzosin (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Lapatinib (Compound)
Alfuzosin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lapatinib
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Alfuzosin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Alfuzosin may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Lapatinib
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Lapatinib |
DB01064 | DB06203 | 1,148 | 1,002 | [
"DDInter987",
"DDInter51"
] | Isoprenaline | Alogliptin | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that this isopropyl analog of epinephrine dilated the bronchi, as well as raising the heart rate and cardiac output, without vasoconstriction.[A233724,A233729] The US patent from 1943 states that this compound had a wider therapeutic index and a stronger action than [adrenaline]. Isoprenaline was granted FDA approval on 19 February 1948. | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013. | Moderate | 1 | [
[
[
1148,
24,
1002
]
],
[
[
1148,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
1148,
21,
28762
],
[
28762,
60,
1002
]
],
[
[
1148,
24,
401
],
[
401,
24,
1002
]
],
[
[
1148,
63,
521
],
[
521,
24,
1002
]
],
[
[
1148,
74,
1674
],
[
1674,
24,
1002
]
],
[
[
1148,
25,
945
],
[
945,
24,
1002
]
],
[
[
1148,
24,
1399
],
[
1399,
63,
1002
]
],
[
[
1148,
62,
175
],
[
175,
24,
1002
]
],
[
[
1148,
64,
695
],
[
695,
24,
1002
]
]
] | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
"Linagliptin",
"{u} (Compound) resembles {v} (Compound)",
"Alogliptin"
]
],
[
[
"Isoprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Alogliptin"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Isoprenaline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Isoprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Isoprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Isoprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
]
] | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Isoprenaline (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Alogliptin (Compound)
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Isoprenaline (Compound) resembles Orciprenaline (Compound) and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Isoprenaline may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Isoprenaline may lead to a major life threatening interaction when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin |
DB00060 | DB00939 | 912 | 1,338 | [
"DDInter947",
"DDInter1135"
] | Interferon beta-1a | Meclofenamic acid | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Moderate | 1 | [
[
[
912,
24,
1338
]
],
[
[
912,
24,
850
],
[
850,
63,
1338
]
],
[
[
912,
24,
482
],
[
482,
24,
1338
]
],
[
[
912,
63,
305
],
[
305,
24,
1338
]
],
[
[
912,
24,
663
],
[
663,
25,
1338
]
],
[
[
912,
24,
39
],
[
39,
64,
1338
]
],
[
[
912,
25,
497
],
[
497,
64,
1338
]
],
[
[
912,
24,
1512
],
[
1512,
35,
1338
]
],
[
[
912,
24,
850
],
[
850,
63,
959
],
[
959,
63,
1338
]
],
[
[
912,
24,
384
],
[
384,
63,
16
],
[
16,
62,
1338
]
]
] | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Interferon beta-1a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linaclotide"
],
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Meclofenamic acid"
]
]
] | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may lead to a major life threatening interaction when taken with Meclofenamic acid
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Meclofenamic acid
Interferon beta-1a may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Meclofenamic acid
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) resembles Meclofenamic acid (Compound) and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Meclofenamic acid |
DB09237 | DB09333 | 1,586 | 278 | [
"DDInter1045",
"DDInter963"
] | Levamlodipine | Iopodic acid | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however. As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity. Levamlodipine was granted FDA approval on 19 December 2019. | Iopodic acid, also known by the name of ipodate, is classified as a cholecystographic agent formed by a weak organic acid that contains a tri-iodinated benzene ring with iodine at positions 2, 4 and 6. Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was developed and filed to the FDA by the company BRACCO. This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada. On September 22, 1981, ipodate was submitted again by the company Schering AG but it is currently under an inactive status. | Moderate | 1 | [
[
[
1586,
24,
278
]
],
[
[
1586,
63,
1648
],
[
1648,
24,
278
]
],
[
[
1586,
63,
1648
],
[
1648,
24,
461
],
[
461,
24,
278
]
],
[
[
1586,
63,
1527
],
[
1527,
63,
461
],
[
461,
24,
278
]
],
[
[
1586,
63,
1512
],
[
1512,
23,
857
],
[
857,
23,
278
]
],
[
[
1586,
63,
1431
],
[
1431,
1,
808
],
[
808,
24,
278
]
],
[
[
1586,
24,
1013
],
[
1013,
62,
857
],
[
857,
23,
278
]
],
[
[
1586,
63,
1479
],
[
1479,
62,
461
],
[
461,
24,
278
]
],
[
[
1586,
63,
1512
],
[
1512,
25,
1527
],
[
1527,
24,
278
]
],
[
[
1586,
63,
512
],
[
512,
62,
857
],
[
857,
23,
278
]
]
] | [
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
],
[
"Iothalamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cholestyramine"
],
[
"Cholestyramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iopodic acid"
]
],
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadopentetic acid"
],
[
"Gadopentetic acid",
"{u} (Compound) resembles {v} (Compound)",
"Gadobenic acid"
],
[
"Gadobenic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tyropanoic acid"
],
[
"Tyropanoic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cholestyramine"
],
[
"Cholestyramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iopodic acid"
]
],
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iothalamic acid"
],
[
"Iothalamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopanoic acid"
],
[
"Iopanoic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cholestyramine"
],
[
"Cholestyramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iopodic acid"
]
]
] | Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid and Iothalamic acid may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Cholestyramine and Cholestyramine may cause a minor interaction that can limit clinical effects when taken with Iopodic acid
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Gadopentetic acid and Gadopentetic acid (Compound) resembles Gadobenic acid (Compound) and Gadobenic acid may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid and Tyropanoic acid may cause a minor interaction that can limit clinical effects when taken with Cholestyramine and Cholestyramine may cause a minor interaction that can limit clinical effects when taken with Iopodic acid
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Iothalamic acid and Iothalamic acid may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic acid and Iopanoic acid may cause a minor interaction that can limit clinical effects when taken with Cholestyramine and Cholestyramine may cause a minor interaction that can limit clinical effects when taken with Iopodic acid |
DB00346 | DB09080 | 472 | 144 | [
"DDInter44",
"DDInter1331"
] | Alfuzosin | Olodaterol | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated symptoms such as shortness of breath, cough, and sputum production. Single doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing. A once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period. Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma. | Moderate | 1 | [
[
[
472,
24,
144
]
],
[
[
472,
25,
1011
],
[
1011,
24,
144
]
],
[
[
472,
24,
543
],
[
543,
24,
144
]
],
[
[
472,
63,
600
],
[
600,
24,
144
]
],
[
[
472,
24,
823
],
[
823,
63,
144
]
],
[
[
472,
25,
982
],
[
982,
63,
144
]
],
[
[
472,
64,
702
],
[
702,
24,
144
]
],
[
[
472,
25,
877
],
[
877,
64,
144
]
],
[
[
472,
25,
1011
],
[
1011,
62,
1247
],
[
1247,
23,
144
]
],
[
[
472,
25,
11
],
[
11,
23,
1247
],
[
1247,
23,
144
]
]
] | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Alfuzosin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Alfuzosin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Alfuzosin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Alfuzosin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olodaterol"
]
],
[
[
"Alfuzosin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Olodaterol"
]
],
[
[
"Alfuzosin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Olodaterol"
]
]
] | Alfuzosin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Alfuzosin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Alfuzosin may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Alfuzosin may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Olodaterol
Alfuzosin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Alfuzosin may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol |
DB00860 | DB01232 | 891 | 1,327 | [
"DDInter1513",
"DDInter1640"
] | Prednisolone | Saquinavir | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared to other antiretroviral therapies. While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%), its current indications require the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and subsequent serum concentrations of saquinavir, thus dramatically improving antiviral activity.[A214382,L3450,L14351] | Moderate | 1 | [
[
[
891,
24,
1327
]
],
[
[
891,
63,
798
],
[
798,
40,
1327
]
],
[
[
891,
24,
915
],
[
915,
40,
1327
]
],
[
[
891,
6,
6648
],
[
6648,
45,
1327
]
],
[
[
891,
21,
28936
],
[
28936,
60,
1327
]
],
[
[
891,
63,
1685
],
[
1685,
24,
1327
]
],
[
[
891,
25,
770
],
[
770,
24,
1327
]
],
[
[
891,
24,
52
],
[
52,
63,
1327
]
],
[
[
891,
23,
688
],
[
688,
24,
1327
]
],
[
[
891,
24,
473
],
[
473,
24,
1327
]
]
] | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} (Compound) resembles {v} (Compound)",
"Saquinavir"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} (Compound) resembles {v} (Compound)",
"Saquinavir"
]
],
[
[
"Prednisolone",
"{u} (Compound) binds {v} (Gene)",
"SLCO1A2"
],
[
"SLCO1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Saquinavir"
]
],
[
[
"Prednisolone",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperhidrosis"
],
[
"Hyperhidrosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Saquinavir"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
],
[
"Dulaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
]
] | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Saquinavir (Compound)
Prednisolone (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Saquinavir (Compound)
Prednisolone (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Saquinavir (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir
Prednisolone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir |
DB04855 | DB09049 | 540 | 1,135 | [
"DDInter602",
"DDInter1261"
] | Dronedarone | Naloxegol | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. Similar to [amiodarone], dronedarone is a multichannel blocker that works to control rhythm and rate in atrial fibrillation. It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium, potassium, and calcium ion channels and inhibiting β-adrenergic receptors.[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems.[A34604,T28] Additionally | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system through the blood-brain barrier. | Major | 2 | [
[
[
540,
25,
1135
]
],
[
[
540,
1,
33
],
[
33,
23,
1135
]
],
[
[
540,
25,
1406
],
[
1406,
62,
1135
]
],
[
[
540,
64,
1424
],
[
1424,
23,
1135
]
],
[
[
540,
25,
1069
],
[
1069,
23,
1135
]
],
[
[
540,
63,
752
],
[
752,
23,
1135
]
],
[
[
540,
24,
578
],
[
578,
23,
1135
]
],
[
[
540,
24,
159
],
[
159,
62,
1135
]
],
[
[
540,
63,
353
],
[
353,
24,
1135
]
],
[
[
540,
25,
982
],
[
982,
63,
1135
]
]
] | [
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
]
],
[
[
"Dronedarone",
"{u} (Compound) resembles {v} (Compound)",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
],
[
"Neratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
]
],
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
]
]
] | Dronedarone (Compound) resembles Amiodarone (Compound) and Amiodarone may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Dronedarone may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Dronedarone may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Dronedarone may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol
Dronedarone may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol |
DB00834 | DB11718 | 932 | 927 | [
"DDInter1215",
"DDInter640"
] | Mifepristone | Encorafenib | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials). | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. | Major | 2 | [
[
[
932,
25,
927
]
],
[
[
932,
23,
112
],
[
112,
23,
927
]
],
[
[
932,
24,
720
],
[
720,
24,
927
]
],
[
[
932,
63,
1324
],
[
1324,
24,
927
]
],
[
[
932,
25,
1491
],
[
1491,
24,
927
]
],
[
[
932,
64,
613
],
[
613,
24,
927
]
],
[
[
932,
25,
484
],
[
484,
63,
927
]
],
[
[
932,
62,
1101
],
[
1101,
24,
927
]
],
[
[
932,
24,
564
],
[
564,
63,
927
]
],
[
[
932,
63,
597
],
[
597,
25,
927
]
]
] | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Mifepristone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Encorafenib"
]
],
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
],
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Irinotecan"
],
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Mifepristone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
],
[
"Abemaciclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
]
] | Mifepristone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Mifepristone may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Mifepristone may lead to a major life threatening interaction when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Mifepristone may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Mifepristone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib and Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may lead to a major life threatening interaction when taken with Encorafenib |
DB00342 | DB08903 | 1,181 | 996 | [
"DDInter1770",
"DDInter170"
] | Terfenadine | Bedaquiline | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP. Consequently, bedaquiline can be used to treat mycobacterial infection, particularly tuberculosis (TB). Although the current standard of TB treatment of anti-TB drugs for 2 months, including 2 key drugs [isoniazid] and [rifampin], is highly effective, the emergence of multidrug-resistant TB (MDR-TB) to [isoniazid] and [rifampin] has substantially worsened patients outcome. Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. Currently, bedaquiline is the last-line anti-TB drug and must only be used in an appropriate combination regimen.[L48506,A261866] | Major | 2 | [
[
[
1181,
25,
996
]
],
[
[
1181,
23,
112
],
[
112,
23,
996
]
],
[
[
1181,
24,
355
],
[
355,
24,
996
]
],
[
[
1181,
24,
144
],
[
144,
63,
996
]
],
[
[
1181,
23,
1387
],
[
1387,
24,
996
]
],
[
[
1181,
63,
1101
],
[
1101,
24,
996
]
],
[
[
1181,
25,
609
],
[
609,
25,
996
]
],
[
[
1181,
24,
124
],
[
124,
64,
996
]
],
[
[
1181,
24,
322
],
[
322,
25,
996
]
],
[
[
1181,
63,
521
],
[
521,
25,
996
]
]
] | [
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bedaquiline"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Terbinafine"
],
[
"Terbinafine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
]
] | Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bedaquiline
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Terfenadine may cause a minor interaction that can limit clinical effects when taken with Terbinafine and Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Terfenadine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Bedaquiline
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Bedaquiline
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Bedaquiline
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may lead to a major life threatening interaction when taken with Bedaquiline |
DB00363 | DB11837 | 695 | 1,297 | [
"DDInter419",
"DDInter1351"
] | Clozapine | Osilodrostat | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia. However, its promiscuity toward the muscarinic and adrenergic receptors can result in other side effects, notably gastrointestinal hypomotility and orthostatic hypotension. [L905,A215552]. Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.[A256713,A256718] However, continued evidence of its effectiveness led to clozapine's eventual reintroduction, although | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013. Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. Cushing's disease), and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication. | Major | 2 | [
[
[
695,
25,
1297
]
],
[
[
695,
23,
112
],
[
112,
23,
1297
]
],
[
[
695,
24,
222
],
[
222,
23,
1297
]
],
[
[
695,
1,
623
],
[
623,
24,
1297
]
],
[
[
695,
24,
401
],
[
401,
24,
1297
]
],
[
[
695,
25,
1555
],
[
1555,
24,
1297
]
],
[
[
695,
40,
867
],
[
867,
24,
1297
]
],
[
[
695,
25,
971
],
[
971,
63,
1297
]
],
[
[
695,
64,
1181
],
[
1181,
24,
1297
]
],
[
[
695,
63,
1324
],
[
1324,
24,
1297
]
]
] | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Clozapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osilodrostat"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osilodrostat"
]
],
[
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound)",
"Olanzapine"
],
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
]
] | Clozapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Clozapine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Clozapine may lead to a major life threatening interaction when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Clozapine (Compound) resembles Olanzapine (Compound) and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Clozapine may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Clozapine may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat |
DB01210 | DB09080 | 668 | 144 | [
"DDInter1050",
"DDInter1331"
] | Levobunolol (ophthalmic) | Olodaterol | Levobunolol is a cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. It has a role as an antiglaucoma drug and a beta-adrenergic antagonist. It is a propanolamine, a cyclic ketone and an aromatic ether. It is a conjugate acid of a levobunolol(1+). It derives from a hydride of a tetralin. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated symptoms such as shortness of breath, cough, and sputum production. Single doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing. A once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period. Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma. | Major | 2 | [
[
[
668,
25,
144
]
],
[
[
668,
24,
1011
],
[
1011,
24,
144
]
],
[
[
668,
64,
455
],
[
455,
24,
144
]
],
[
[
668,
63,
1148
],
[
1148,
24,
144
]
],
[
[
668,
25,
659
],
[
659,
63,
144
]
],
[
[
668,
1,
699
],
[
699,
25,
144
]
],
[
[
668,
40,
729
],
[
729,
25,
144
]
],
[
[
668,
24,
1011
],
[
1011,
62,
1247
],
[
1247,
23,
144
]
],
[
[
668,
64,
455
],
[
455,
24,
956
],
[
956,
24,
144
]
],
[
[
668,
63,
1148
],
[
1148,
63,
956
],
[
956,
24,
144
]
]
] | [
[
[
"Levobunolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olodaterol"
]
],
[
[
"Levobunolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Levobunolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Levobunolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Levobunolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Levobunolol",
"{u} (Compound) resembles {v} (Compound)",
"Nadolol"
],
[
"Nadolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olodaterol"
]
],
[
[
"Levobunolol",
"{u} (Compound) resembles {v} (Compound)",
"Penbutolol"
],
[
"Penbutolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olodaterol"
]
],
[
[
"Levobunolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Olodaterol"
]
],
[
[
"Levobunolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Levobunolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
]
] | Levobunolol may lead to a major life threatening interaction when taken with Olodaterol
Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Levobunolol may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Levobunolol may lead to a major life threatening interaction when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Levobunolol (Compound) resembles Nadolol (Compound) and Nadolol may lead to a major life threatening interaction when taken with Olodaterol
Levobunolol (Compound) resembles Penbutolol (Compound) and Penbutolol may lead to a major life threatening interaction when taken with Olodaterol
Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Levobunolol may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol |
DB00218 | DB00987 | 1,176 | 1,224 | [
"DDInter1247",
"DDInter460"
] | Moxifloxacin | Cytarabine | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) | Minor | 0 | [
[
[
1176,
23,
1224
]
],
[
[
1176,
6,
3199
],
[
3199,
57,
1224
]
],
[
[
1176,
1,
872
],
[
872,
62,
1224
]
],
[
[
1176,
1,
739
],
[
739,
23,
1224
]
],
[
[
1176,
25,
322
],
[
322,
24,
1224
]
],
[
[
1176,
23,
134
],
[
134,
24,
1224
]
],
[
[
1176,
24,
850
],
[
850,
63,
1224
]
],
[
[
1176,
24,
267
],
[
267,
24,
1224
]
],
[
[
1176,
25,
77
],
[
77,
63,
1224
]
],
[
[
1176,
23,
60
],
[
60,
63,
1224
]
]
] | [
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cytarabine"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) binds {v} (Gene)",
"TOP2A"
],
[
"TOP2A",
"{u} (Gene) is downregulated by {v} (Compound)",
"Cytarabine"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cytarabine"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cytarabine"
]
],
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
],
[
"Capecitabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
]
] | Moxifloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Cytarabine (Compound)
Moxifloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine
Moxifloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine
Moxifloxacin may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine
Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine
Moxifloxacin may lead to a major life threatening interaction when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine
Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine and Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine |
DB00290 | DB01610 | 329 | 248 | [
"DDInter219",
"DDInter1912"
] | Bleomycin | Valganciclovir | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
329,
24,
248
]
],
[
[
329,
24,
563
],
[
563,
1,
248
]
],
[
[
329,
21,
29209
],
[
29209,
60,
248
]
],
[
[
329,
24,
1238
],
[
1238,
24,
248
]
],
[
[
329,
25,
507
],
[
507,
63,
248
]
],
[
[
329,
63,
1648
],
[
1648,
24,
248
]
],
[
[
329,
25,
770
],
[
770,
24,
248
]
],
[
[
329,
24,
738
],
[
738,
63,
248
]
],
[
[
329,
25,
375
],
[
375,
64,
248
]
],
[
[
329,
64,
581
],
[
581,
25,
248
]
]
] | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Valganciclovir"
]
],
[
[
"Bleomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Anorexia"
],
[
"Anorexia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Valganciclovir"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
],
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
],
[
"Samarium (153Sm) lexidronam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valganciclovir"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valganciclovir"
]
]
] | Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Bleomycin (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Valganciclovir (Compound)
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin and Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Bleomycin may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam and Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Bleomycin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Bleomycin may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Valganciclovir
Bleomycin may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Valganciclovir |
DB00169 | DB01045 | 386 | 463 | [
"DDInter367",
"DDInter1590"
] | Cholecalciferol | Rifampicin | Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight. Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-derived form, vitamin D2 (ergocalciferol), are considered the main forms of vitamin d and are found in various types of food for daily intake. Structurally, ergocalciferol differs from cholecalciferol in that it possesses a double bond between C22 and C23 and has an additional methyl group at C24. Finally, ergocalciferol is pharmacologically less potent than cholecalciferol, which makes vitamin D3 the preferred agent for medical use. Appropriate levels of vitamin D must be upheld in the body in order to maintain calcium and phosphorus levels in a | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) | Moderate | 1 | [
[
[
386,
24,
463
]
],
[
[
386,
24,
690
],
[
690,
40,
463
]
],
[
[
386,
6,
10215
],
[
10215,
45,
463
]
],
[
[
386,
25,
1196
],
[
1196,
63,
463
]
],
[
[
386,
25,
1041
],
[
1041,
24,
463
]
],
[
[
386,
75,
160
],
[
160,
24,
463
]
],
[
[
386,
24,
286
],
[
286,
63,
463
]
],
[
[
386,
24,
690
],
[
690,
1,
1389
],
[
1389,
40,
463
]
],
[
[
386,
6,
10215
],
[
10215,
45,
1264
],
[
1264,
62,
463
]
],
[
[
386,
6,
7603
],
[
7603,
45,
608
],
[
608,
23,
463
]
]
] | [
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],
[
"Rifabutin",
"{u} (Compound) resembles {v} (Compound)",
"Rifampicin"
]
],
[
[
"Cholecalciferol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Rifampicin"
]
],
[
[
"Cholecalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxercalciferol"
],
[
"Doxercalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Cholecalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paricalcitol"
],
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Cholecalciferol",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Calcifediol"
],
[
"Calcifediol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],
[
"Rifabutin",
"{u} (Compound) resembles {v} (Compound)",
"Rifapentine"
],
[
"Rifapentine",
"{u} (Compound) resembles {v} (Compound)",
"Rifampicin"
]
],
[
[
"Cholecalciferol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rifampicin"
]
],
[
[
"Cholecalciferol",
"{u} (Compound) binds {v} (Gene)",
"CYP2B6"
],
[
"CYP2B6",
"{u} (Gene) is bound by {v} (Compound)",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rifampicin"
]
]
] | Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound)
Cholecalciferol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Rifampicin (Compound)
Cholecalciferol may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Cholecalciferol may lead to a major life threatening interaction when taken with Paricalcitol and Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Cholecalciferol (Compound) resembles Calcifediol (Compound) and Cholecalciferol may lead to a major life threatening interaction when taken with Calcifediol and Calcifediol may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifapentine (Compound) and Rifapentine (Compound) resembles Rifampicin (Compound)
Cholecalciferol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Doxepin (Compound) and Doxepin may cause a minor interaction that can limit clinical effects when taken with Rifampicin
Cholecalciferol (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Rifampicin |
DB06824 | DB09104 | 29 | 286 | [
"DDInter1864",
"DDInter1118"
] | Triethylenetetramine | Magnesium hydroxide | Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, [spermidine] and [spermine]. TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925. Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease, TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and tolerant to [penicillamine]. TETA has been investigated in clinical trials for the treatment of heart failure in patients with diabetes.[A18804,A19332,A19333,A19334,A19335] | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers). | Moderate | 1 | [
[
[
29,
24,
286
]
],
[
[
29,
63,
954
],
[
954,
23,
286
]
],
[
[
29,
63,
1283
],
[
1283,
24,
286
]
],
[
[
29,
24,
428
],
[
428,
63,
286
]
],
[
[
29,
63,
954
],
[
954,
24,
820
],
[
820,
23,
286
]
],
[
[
29,
63,
1283
],
[
1283,
23,
481
],
[
481,
23,
286
]
],
[
[
29,
24,
428
],
[
428,
62,
752
],
[
752,
23,
286
]
],
[
[
29,
24,
853
],
[
853,
63,
839
],
[
839,
24,
286
]
],
[
[
29,
63,
1596
],
[
1596,
62,
752
],
[
752,
23,
286
]
],
[
[
29,
23,
1193
],
[
1193,
62,
1096
],
[
1096,
24,
286
]
]
] | [
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
],
[
"Ferrous fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quazepam"
],
[
"Quazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
],
[
"Ferrous fumarate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
],
[
"Magnesium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
],
[
"Iron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
]
] | Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Quazepam and Quazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride and Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Triethylenetetramine may cause a moderate interaction that could exacerbate diseases when taken with Iron and Iron may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Triethylenetetramine may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide |
DB00224 | DB04868 | 215 | 478 | [
"DDInter917",
"DDInter1293"
] | Indinavir | Nilotinib | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML. | Major | 2 | [
[
[
215,
25,
478
]
],
[
[
215,
25,
1468
],
[
1468,
63,
478
]
],
[
[
215,
6,
6017
],
[
6017,
45,
478
]
],
[
[
215,
18,
10375
],
[
10375,
57,
478
]
],
[
[
215,
21,
28963
],
[
28963,
60,
478
]
],
[
[
215,
25,
1135
],
[
1135,
62,
478
]
],
[
[
215,
24,
466
],
[
466,
62,
478
]
],
[
[
215,
24,
1040
],
[
1040,
63,
478
]
],
[
[
215,
23,
303
],
[
303,
24,
478
]
],
[
[
215,
24,
126
],
[
126,
24,
478
]
]
] | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Indinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Indinavir",
"{u} (Compound) downregulates {v} (Gene)",
"RPS4Y1"
],
[
"RPS4Y1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Indinavir",
"{u} (Compound) causes {v} (Side Effect)",
"Anxiety"
],
[
"Anxiety",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Indinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
]
] | Indinavir may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Indinavir (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Indinavir (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Nilotinib (Compound)
Indinavir (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Indinavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Indinavir may cause a minor interaction that can limit clinical effects when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib |
DB00195 | DB00938 | 726 | 455 | [
"DDInter198",
"DDInter1635"
] | Betaxolol (ophthalmic) | Salmeterol | Betaxolol is a propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydoxy is substituted by a 4-[2-(cyclopropylmethoxy)ethyl]phenyl group and one of the hydrogens attached to the amino group is substituted by isopropyl. It is a selective beta1-receptor blocker and is used in the treatment of glaucoma as well as hypertension, arrhythmias, and coronary heart disease. It is also used to reduce non-fatal cardiac events in patients with heart failure. It has a role as a beta-adrenergic antagonist, an antihypertensive agent and a sympatholytic agent. | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994. | Moderate | 1 | [
[
[
726,
24,
455
]
],
[
[
726,
24,
688
],
[
688,
63,
455
]
],
[
[
726,
6,
3576
],
[
3576,
45,
455
]
],
[
[
726,
21,
29095
],
[
29095,
60,
455
]
],
[
[
726,
1,
1121
],
[
1121,
24,
455
]
],
[
[
726,
25,
1031
],
[
1031,
24,
455
]
],
[
[
726,
1,
819
],
[
819,
63,
455
]
],
[
[
726,
24,
1636
],
[
1636,
24,
455
]
],
[
[
726,
1,
887
],
[
887,
64,
455
]
],
[
[
726,
24,
688
],
[
688,
64,
1523
],
[
1523,
25,
455
]
]
] | [
[
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Betaxolol",
"{u} (Compound) binds {v} (Gene)",
"ADRB2"
],
[
"ADRB2",
"{u} (Gene) is bound by {v} (Compound)",
"Salmeterol"
]
],
[
[
"Betaxolol",
"{u} (Compound) causes {v} (Side Effect)",
"Ear pain"
],
[
"Ear pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Salmeterol"
]
],
[
[
"Betaxolol",
"{u} (Compound) resembles {v} (Compound)",
"Bisoprolol"
],
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Betaxolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Betaxolol",
"{u} (Compound) resembles {v} (Compound)",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Betaxolol",
"{u} (Compound) resembles {v} (Compound)",
"Pindolol"
],
[
"Pindolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
]
],
[
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
]
]
] | Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Betaxolol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Salmeterol (Compound)
Betaxolol (Compound) causes Ear pain (Side Effect) and Ear pain (Side Effect) is caused by Salmeterol (Compound)
Betaxolol (Compound) resembles Bisoprolol (Compound) and Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Betaxolol may lead to a major life threatening interaction when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Betaxolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Betaxolol (Compound) resembles Pindolol (Compound) and Pindolol may lead to a major life threatening interaction when taken with Salmeterol
Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may lead to a major life threatening interaction when taken with Labetalol and Labetalol may lead to a major life threatening interaction when taken with Salmeterol |
DB06691 | DB14509 | 849 | 1,399 | [
"DDInter1155",
"DDInter1081"
] | Mepyramine | Lithium carbonate | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
849,
24,
1399
]
],
[
[
849,
63,
506
],
[
506,
24,
1399
]
],
[
[
849,
24,
407
],
[
407,
24,
1399
]
],
[
[
849,
74,
100
],
[
100,
24,
1399
]
],
[
[
849,
63,
222
],
[
222,
25,
1399
]
],
[
[
849,
63,
506
],
[
506,
24,
1374
],
[
1374,
24,
1399
]
],
[
[
849,
63,
820
],
[
820,
63,
874
],
[
874,
23,
1399
]
],
[
[
849,
63,
717
],
[
717,
63,
506
],
[
506,
24,
1399
]
],
[
[
849,
24,
407
],
[
407,
63,
506
],
[
506,
24,
1399
]
],
[
[
849,
74,
100
],
[
100,
63,
506
],
[
506,
24,
1399
]
]
] | [
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Mepyramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
],
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Mepyramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
]
] | Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Mepyramine (Compound) resembles Brompheniramine (Compound) and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Lithium carbonate
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide and Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Mepyramine (Compound) resembles Brompheniramine (Compound) and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate |
DB01267 | DB09045 | 519 | 52 | [
"DDInter1381",
"DDInter607"
] | Paliperidone | Dulaglutide | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749] | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events. It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations. | Moderate | 1 | [
[
[
519,
24,
52
]
],
[
[
519,
63,
170
],
[
170,
23,
52
]
],
[
[
519,
63,
609
],
[
609,
24,
52
]
],
[
[
519,
25,
1154
],
[
1154,
24,
52
]
],
[
[
519,
24,
1491
],
[
1491,
24,
52
]
],
[
[
519,
24,
1296
],
[
1296,
63,
52
]
],
[
[
519,
40,
1664
],
[
1664,
24,
52
]
],
[
[
519,
63,
170
],
[
170,
62,
1103
],
[
1103,
23,
52
]
],
[
[
519,
63,
609
],
[
609,
24,
170
],
[
170,
23,
52
]
],
[
[
519,
63,
870
],
[
870,
1,
1103
],
[
1103,
23,
52
]
]
] | [
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Paliperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Paliperidone",
"{u} (Compound) resembles {v} (Compound)",
"Risperidone"
],
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
]
]
] | Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Paliperidone may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Paliperidone (Compound) resembles Risperidone (Compound) and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Dulaglutide |
DB01406 | DB06203 | 984 | 1,002 | [
"DDInter472",
"DDInter51"
] | Danazol | Alogliptin | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013. | Moderate | 1 | [
[
[
984,
24,
1002
]
],
[
[
984,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
984,
6,
8374
],
[
8374,
45,
1002
]
],
[
[
984,
21,
28873
],
[
28873,
60,
1002
]
],
[
[
984,
63,
176
],
[
176,
24,
1002
]
],
[
[
984,
40,
35
],
[
35,
24,
1002
]
],
[
[
984,
24,
1296
],
[
1296,
63,
1002
]
],
[
[
984,
62,
222
],
[
222,
24,
1002
]
],
[
[
984,
1,
1336
],
[
1336,
24,
1002
]
],
[
[
984,
24,
1281
],
[
1281,
6,
4405
],
[
4405,
45,
1002
]
]
] | [
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
"Linagliptin",
"{u} (Compound) resembles {v} (Compound)",
"Alogliptin"
]
],
[
[
"Danazol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Alogliptin"
]
],
[
[
"Danazol",
"{u} (Compound) causes {v} (Side Effect)",
"Pancreatitis"
],
[
"Pancreatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Alogliptin"
]
],
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Danazol",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
],
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Danazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Danazol",
"{u} (Compound) resembles {v} (Compound)",
"Etonogestrel"
],
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
"Linagliptin",
"{u} (Compound) binds {v} (Gene)",
"DPP4"
],
[
"DPP4",
"{u} (Gene) is bound by {v} (Compound)",
"Alogliptin"
]
]
] | Danazol may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Danazol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alogliptin (Compound)
Danazol (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Alogliptin (Compound)
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Danazol (Compound) resembles Quinestrol (Compound) and Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Danazol may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Danazol (Compound) resembles Etonogestrel (Compound) and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) binds DPP4 (Gene) and DPP4 (Gene) is bound by Alogliptin (Compound) |
DB01069 | DB08824 | 401 | 591 | [
"DDInter1533",
"DDInter959"
] | Promethazine | Ioflupane I-123 | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] | Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes. | Moderate | 1 | [
[
[
401,
24,
591
]
],
[
[
401,
21,
28762
],
[
28762,
60,
591
]
],
[
[
401,
63,
109
],
[
109,
24,
591
]
],
[
[
401,
25,
924
],
[
924,
24,
591
]
],
[
[
401,
75,
684
],
[
684,
24,
591
]
],
[
[
401,
74,
1630
],
[
1630,
24,
591
]
],
[
[
401,
24,
795
],
[
795,
24,
591
]
],
[
[
401,
64,
78
],
[
78,
24,
591
]
],
[
[
401,
24,
1241
],
[
1241,
63,
591
]
],
[
[
401,
21,
28762
],
[
28762,
60,
109
],
[
109,
24,
591
]
]
] | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Promethazine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ioflupane I-123"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
],
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Promethazine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Promethazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
],
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pemoline"
],
[
"Pemoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
],
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
],
[
"Brexpiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Promethazine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
]
] | Promethazine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ioflupane I-123 (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Promethazine may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Promethazine (Compound) resembles Thioridazine (Compound) and Promethazine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Promethazine (Compound) resembles Perphenazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Pemoline and Pemoline may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Promethazine may lead to a major life threatening interaction when taken with Droperidol and Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole and Brexpiprazole may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Promethazine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123 |
DB00163 | DB11988 | 1,461 | 270 | [
"DDInter1943",
"DDInter1321"
] | Vitamin E | Ocrelizumab | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are currently being researched for use in the treatment of diseases causing bone loss, cardiovascular diseases, diabetes mellitus and associated comorbidities, eye diseases, inflammatory diseases (including skin conditions), lipid disorders, neurological diseases, and radiation damage. Though this research is so far inconclusive, vitamin E remains a popular supplement and is generally considered safe by the FDA[FDA Label]. | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS.[A18875,A251745] MS is a chronic, inflammatory, autoimmune disease of the central nervous system that leads to neurological disabilities and a significantly reduced quality of life. Most patients with MS experience episodes of relapses with worsening function, followed by recovery periods or remissions. Primary progressive multiple sclerosis (PPMS) accounts for 10-15% of the overall population of patients with MS, and leads to the gradual worsening of neurologic disability from symptom onset, often without early relapses or remissions . Developed by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevus for intravenous injection. It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a]. In phase 3 clinical trials of patients with PPMS, treatment with ocrelizumab led to lower clinical and MRI progression rates compared to placebo. | Minor | 0 | [
[
[
1461,
23,
270
]
],
[
[
1461,
24,
134
],
[
134,
24,
270
]
],
[
[
1461,
23,
1019
],
[
1019,
24,
270
]
],
[
[
1461,
62,
1309
],
[
1309,
24,
270
]
],
[
[
1461,
23,
398
],
[
398,
63,
270
]
],
[
[
1461,
23,
976
],
[
976,
25,
270
]
],
[
[
1461,
23,
676
],
[
676,
64,
270
]
],
[
[
1461,
62,
1066
],
[
1066,
25,
270
]
],
[
[
1461,
24,
1064
],
[
1064,
25,
270
]
],
[
[
1461,
24,
134
],
[
134,
24,
1060
],
[
1060,
63,
270
]
]
] | [
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Basiliximab"
],
[
"Basiliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tildrakizumab"
],
[
"Tildrakizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],
[
"Enfortumab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
]
] | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Basiliximab and Basiliximab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tildrakizumab and Tildrakizumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Ocrelizumab
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Ocrelizumab
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Ocrelizumab
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Ocrelizumab
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab |
DB06176 | DB08827 | 1,342 | 990 | [
"DDInter1616",
"DDInter1085"
] | Romidepsin | Lomitapide | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Moderate | 1 | [
[
[
1342,
24,
990
]
],
[
[
1342,
63,
1080
],
[
1080,
1,
990
]
],
[
[
1342,
24,
1362
],
[
1362,
63,
990
]
],
[
[
1342,
63,
77
],
[
77,
24,
990
]
],
[
[
1342,
24,
1491
],
[
1491,
24,
990
]
],
[
[
1342,
25,
985
],
[
985,
63,
990
]
],
[
[
1342,
63,
79
],
[
79,
25,
990
]
],
[
[
1342,
24,
1468
],
[
1468,
64,
990
]
],
[
[
1342,
25,
1510
],
[
1510,
64,
990
]
],
[
[
1342,
25,
39
],
[
39,
25,
990
]
]
] | [
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
],
[
"Conivaptan",
"{u} (Compound) resembles {v} (Compound)",
"Lomitapide"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
]
] | Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan and Conivaptan (Compound) resembles Lomitapide (Compound)
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Romidepsin may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may lead to a major life threatening interaction when taken with Lomitapide
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may lead to a major life threatening interaction when taken with Lomitapide
Romidepsin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Lomitapide
Romidepsin may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Lomitapide |
DB00653 | DB00910 | 544 | 1,041 | [
"DDInter1120",
"DDInter1394"
] | Magnesium sulfate | Paricalcitol | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083) | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | Moderate | 1 | [
[
[
544,
24,
1041
]
],
[
[
544,
63,
386
],
[
386,
25,
1041
]
],
[
[
544,
24,
1098
],
[
1098,
64,
1041
]
],
[
[
544,
21,
29263
],
[
29263,
60,
1041
]
],
[
[
544,
24,
1473
],
[
1473,
63,
1041
]
],
[
[
544,
25,
241
],
[
241,
64,
1041
]
],
[
[
544,
63,
1331
],
[
1331,
36,
1041
]
],
[
[
544,
63,
386
],
[
386,
40,
1113
],
[
1113,
1,
1041
]
],
[
[
544,
63,
160
],
[
160,
36,
386
],
[
386,
25,
1041
]
],
[
[
544,
24,
1098
],
[
1098,
64,
386
],
[
386,
25,
1041
]
]
] | [
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paricalcitol"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paricalcitol"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dihydrotachysterol"
],
[
"Dihydrotachysterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paricalcitol"
]
],
[
[
"Magnesium sulfate",
"{u} (Compound) causes {v} (Side Effect)",
"Intoxication"
],
[
"Intoxication",
"{u} (Side Effect) is caused by {v} (Compound)",
"Paricalcitol"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium gluconate"
],
[
"Magnesium gluconate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paricalcitol"
]
],
[
[
"Magnesium sulfate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
],
[
"Erdafitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paricalcitol"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ergocalciferol"
],
[
"Ergocalciferol",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Paricalcitol"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} (Compound) resembles {v} (Compound)",
"Calcitriol"
],
[
"Calcitriol",
"{u} (Compound) resembles {v} (Compound)",
"Paricalcitol"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcifediol"
],
[
"Calcifediol",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paricalcitol"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dihydrotachysterol"
],
[
"Dihydrotachysterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paricalcitol"
]
]
] | Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Cholecalciferol and Cholecalciferol may lead to a major life threatening interaction when taken with Paricalcitol
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Dihydrotachysterol and Dihydrotachysterol may lead to a major life threatening interaction when taken with Paricalcitol
Magnesium sulfate (Compound) causes Intoxication (Side Effect) and Intoxication (Side Effect) is caused by Paricalcitol (Compound)
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate and Magnesium gluconate may cause a moderate interaction that could exacerbate diseases when taken with Paricalcitol
Magnesium sulfate may lead to a major life threatening interaction when taken with Erdafitinib and Erdafitinib may lead to a major life threatening interaction when taken with Paricalcitol
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Ergocalciferol and Ergocalciferol (Compound) resembles Paricalcitol (Compound) and Ergocalciferol may lead to a major life threatening interaction when taken with Paricalcitol
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Cholecalciferol and Cholecalciferol (Compound) resembles Calcitriol (Compound) and Calcitriol (Compound) resembles Paricalcitol (Compound)
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Calcifediol and Calcifediol (Compound) resembles Cholecalciferol (Compound) and Calcifediol may lead to a major life threatening interaction when taken with Cholecalciferol and Cholecalciferol may lead to a major life threatening interaction when taken with Paricalcitol
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Dihydrotachysterol and Dihydrotachysterol may lead to a major life threatening interaction when taken with Cholecalciferol and Cholecalciferol may lead to a major life threatening interaction when taken with Paricalcitol |
DB00060 | DB08903 | 912 | 996 | [
"DDInter947",
"DDInter170"
] | Interferon beta-1a | Bedaquiline | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP. Consequently, bedaquiline can be used to treat mycobacterial infection, particularly tuberculosis (TB). Although the current standard of TB treatment of anti-TB drugs for 2 months, including 2 key drugs [isoniazid] and [rifampin], is highly effective, the emergence of multidrug-resistant TB (MDR-TB) to [isoniazid] and [rifampin] has substantially worsened patients outcome. Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. Currently, bedaquiline is the last-line anti-TB drug and must only be used in an appropriate combination regimen.[L48506,A261866] | Moderate | 1 | [
[
[
912,
24,
996
]
],
[
[
912,
24,
713
],
[
713,
63,
996
]
],
[
[
912,
24,
848
],
[
848,
24,
996
]
],
[
[
912,
25,
593
],
[
593,
24,
996
]
],
[
[
912,
63,
491
],
[
491,
24,
996
]
],
[
[
912,
24,
609
],
[
609,
25,
996
]
],
[
[
912,
25,
1377
],
[
1377,
25,
996
]
],
[
[
912,
24,
1383
],
[
1383,
64,
996
]
],
[
[
912,
24,
888
],
[
888,
36,
996
]
],
[
[
912,
24,
713
],
[
713,
63,
350
],
[
350,
24,
996
]
]
] | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Interferon beta-1a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Interferon beta-1a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
]
] | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Interferon beta-1a may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Bedaquiline
Interferon beta-1a may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Bedaquiline
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may lead to a major life threatening interaction when taken with Bedaquiline
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen (Compound) resembles Bedaquiline (Compound) and Tamoxifen may lead to a major life threatening interaction when taken with Bedaquiline
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline |
DB06176 | DB08904 | 1,342 | 375 | [
"DDInter1616",
"DDInter342"
] | Romidepsin | Certolizumab pegol | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019. | Major | 2 | [
[
[
1342,
25,
375
]
],
[
[
1342,
63,
1461
],
[
1461,
23,
375
]
],
[
[
1342,
24,
200
],
[
200,
63,
375
]
],
[
[
1342,
25,
1593
],
[
1593,
24,
375
]
],
[
[
1342,
63,
66
],
[
66,
24,
375
]
],
[
[
1342,
64,
494
],
[
494,
24,
375
]
],
[
[
1342,
24,
1430
],
[
1430,
24,
375
]
],
[
[
1342,
62,
112
],
[
112,
24,
375
]
],
[
[
1342,
64,
1066
],
[
1066,
25,
375
]
],
[
[
1342,
24,
1250
],
[
1250,
25,
375
]
]
] | [
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Romidepsin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
]
] | Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Romidepsin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Romidepsin may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Romidepsin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Romidepsin may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Certolizumab pegol |
DB00424 | DB08815 | 19 | 154 | [
"DDInter896",
"DDInter1104"
] | Hyoscyamine | Lurasidone | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimuscarinic properties.[L31548,L31553] Although hyoscyamine is marketed in the United States, it is not FDA approved.[L31548,L31553] | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
19,
24,
154
]
],
[
[
19,
21,
28963
],
[
28963,
60,
154
]
],
[
[
19,
24,
100
],
[
100,
24,
154
]
],
[
[
19,
63,
999
],
[
999,
24,
154
]
],
[
[
19,
24,
103
],
[
103,
63,
154
]
],
[
[
19,
63,
475
],
[
475,
25,
154
]
],
[
[
19,
24,
1311
],
[
1311,
25,
154
]
],
[
[
19,
21,
28963
],
[
28963,
60,
1085
],
[
1085,
1,
154
]
],
[
[
19,
21,
28751
],
[
28751,
60,
1532
],
[
1532,
24,
154
]
],
[
[
19,
24,
100
],
[
100,
6,
8374
],
[
8374,
45,
154
]
]
] | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Hyoscyamine",
"{u} (Compound) causes {v} (Side Effect)",
"Anxiety"
],
[
"Anxiety",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lurasidone"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
],
[
"Acrivastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurasidone"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurasidone"
]
],
[
[
"Hyoscyamine",
"{u} (Compound) causes {v} (Side Effect)",
"Anxiety"
],
[
"Anxiety",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ziprasidone"
],
[
"Ziprasidone",
"{u} (Compound) resembles {v} (Compound)",
"Lurasidone"
]
],
[
[
"Hyoscyamine",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lurasidone"
]
]
] | Hyoscyamine (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Lurasidone (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine and Acrivastine may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Lurasidone
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may lead to a major life threatening interaction when taken with Lurasidone
Hyoscyamine (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Ziprasidone (Compound) and Ziprasidone (Compound) resembles Lurasidone (Compound)
Hyoscyamine (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lurasidone (Compound) |
DB00559 | DB09143 | 152 | 313 | [
"DDInter223",
"DDInter1701"
] | Bosentan | Sonidegib | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Major | 2 | [
[
[
152,
25,
313
]
],
[
[
152,
24,
478
],
[
478,
24,
313
]
],
[
[
152,
25,
484
],
[
484,
63,
313
]
],
[
[
152,
24,
1320
],
[
1320,
63,
313
]
],
[
[
152,
63,
752
],
[
752,
24,
313
]
],
[
[
152,
62,
1101
],
[
1101,
24,
313
]
],
[
[
152,
24,
129
],
[
129,
25,
313
]
],
[
[
152,
63,
600
],
[
600,
25,
313
]
],
[
[
152,
25,
283
],
[
283,
64,
313
]
],
[
[
152,
25,
760
],
[
760,
25,
313
]
]
] | [
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Bosentan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
]
] | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Bosentan may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Bosentan may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Sonidegib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Sonidegib
Bosentan may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Sonidegib
Bosentan may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Sonidegib |
DB00361 | DB06717 | 134 | 875 | [
"DDInter1939",
"DDInter778"
] | Vinorelbine | Fosaprepitant | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting. A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug. | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
134,
24,
875
]
],
[
[
134,
24,
723
],
[
723,
1,
875
]
],
[
[
134,
21,
29122
],
[
29122,
60,
875
]
],
[
[
134,
63,
1101
],
[
1101,
23,
875
]
],
[
[
134,
25,
760
],
[
760,
63,
875
]
],
[
[
134,
24,
86
],
[
86,
24,
875
]
],
[
[
134,
24,
351
],
[
351,
63,
875
]
],
[
[
134,
63,
600
],
[
600,
24,
875
]
],
[
[
134,
25,
609
],
[
609,
24,
875
]
],
[
[
134,
24,
484
],
[
484,
64,
875
]
]
] | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} (Compound) resembles {v} (Compound)",
"Fosaprepitant"
]
],
[
[
"Vinorelbine",
"{u} (Compound) causes {v} (Side Effect)",
"Mediastinal disorder"
],
[
"Mediastinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fosaprepitant"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosaprepitant"
]
]
] | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Vinorelbine (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Fosaprepitant (Compound)
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Fosaprepitant
Vinorelbine may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Vinorelbine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may lead to a major life threatening interaction when taken with Fosaprepitant |
DB00533 | DB08816 | 1,416 | 578 | [
"DDInter1613",
"DDInter1802"
] | Rofecoxib | Ticagrelor | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. Rofecoxib has a half-life of 17 hours and its mean oral bioavailability at therapeutically recommended doses of 125, 25, and 50 mg is approximately 93%. The proteins that rofecoxib target include elastin and prostaglandin G/H synthase 2 | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Moderate | 1 | [
[
[
1416,
24,
578
]
],
[
[
1416,
63,
1578
],
[
1578,
24,
578
]
],
[
[
1416,
24,
1220
],
[
1220,
24,
578
]
],
[
[
1416,
24,
840
],
[
840,
63,
578
]
],
[
[
1416,
25,
629
],
[
629,
24,
578
]
],
[
[
1416,
24,
1046
],
[
1046,
25,
578
]
],
[
[
1416,
24,
498
],
[
498,
64,
578
]
],
[
[
1416,
63,
1578
],
[
1578,
23,
297
],
[
297,
62,
578
]
],
[
[
1416,
24,
1220
],
[
1220,
6,
4973
],
[
4973,
45,
578
]
],
[
[
1416,
24,
1347
],
[
1347,
5,
11576
],
[
11576,
44,
578
]
]
] | [
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
],
[
"Vorapaxar",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Rofecoxib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caplacizumab"
],
[
"Caplacizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Ticagrelor"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} (Compound) treats {v} (Disease)",
"coronary artery disease"
],
[
"coronary artery disease",
"{u} (Disease) is treated by {v} (Compound)",
"Ticagrelor"
]
]
] | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar and Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Rofecoxib may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab and Caplacizumab may lead to a major life threatening interaction when taken with Ticagrelor
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban and Edoxaban may lead to a major life threatening interaction when taken with Ticagrelor
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound)
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel (Compound) treats coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Ticagrelor (Compound) |
DB00872 | DB11837 | 1,080 | 1,297 | [
"DDInter438",
"DDInter1351"
] | Conivaptan | Osilodrostat | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013. Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. Cushing's disease), and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication. | Major | 2 | [
[
[
1080,
25,
1297
]
],
[
[
1080,
25,
1135
],
[
1135,
23,
1297
]
],
[
[
1080,
24,
466
],
[
466,
62,
1297
]
],
[
[
1080,
24,
222
],
[
222,
23,
1297
]
],
[
[
1080,
25,
1320
],
[
1320,
63,
1297
]
],
[
[
1080,
25,
578
],
[
578,
24,
1297
]
],
[
[
1080,
63,
1424
],
[
1424,
24,
1297
]
],
[
[
1080,
64,
1181
],
[
1181,
24,
1297
]
],
[
[
1080,
62,
126
],
[
126,
24,
1297
]
],
[
[
1080,
24,
659
],
[
659,
24,
1297
]
]
] | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osilodrostat"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osilodrostat"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osilodrostat"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Conivaptan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
]
] | Conivaptan may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Conivaptan may lead to a major life threatening interaction when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Conivaptan may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Conivaptan may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Conivaptan may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat |
DB00401 | DB01041 | 84 | 770 | [
"DDInter1298",
"DDInter1789"
] | Nisoldipine | Thalidomide | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone or in combination with other agents in the management of hypertension. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence. | Moderate | 1 | [
[
[
84,
24,
770
]
],
[
[
84,
6,
7524
],
[
7524,
45,
770
]
],
[
[
84,
7,
7669
],
[
7669,
46,
770
]
],
[
[
84,
21,
29598
],
[
29598,
60,
770
]
],
[
[
84,
24,
849
],
[
849,
63,
770
]
],
[
[
84,
24,
1614
],
[
1614,
24,
770
]
],
[
[
84,
40,
1428
],
[
1428,
24,
770
]
],
[
[
84,
1,
1081
],
[
1081,
24,
770
]
],
[
[
84,
63,
999
],
[
999,
24,
770
]
],
[
[
84,
25,
1166
],
[
1166,
24,
770
]
]
] | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Nisoldipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Thalidomide"
]
],
[
[
"Nisoldipine",
"{u} (Compound) upregulates {v} (Gene)",
"DDIT4"
],
[
"DDIT4",
"{u} (Gene) is upregulated by {v} (Compound)",
"Thalidomide"
]
],
[
[
"Nisoldipine",
"{u} (Compound) causes {v} (Side Effect)",
"Cellulitis"
],
[
"Cellulitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Thalidomide"
]
],
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Nisoldipine",
"{u} (Compound) resembles {v} (Compound)",
"Isradipine"
],
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Nisoldipine",
"{u} (Compound) resembles {v} (Compound)",
"Nicardipine"
],
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Nisoldipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
]
] | Nisoldipine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Thalidomide (Compound)
Nisoldipine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Thalidomide (Compound)
Nisoldipine (Compound) causes Cellulitis (Side Effect) and Cellulitis (Side Effect) is caused by Thalidomide (Compound)
Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Nisoldipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Nisoldipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Nisoldipine may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide |
DB01176 | DB01181 | 537 | 1,532 | [
"DDInter453",
"DDInter906"
] | Cyclizine | Ifosfamide | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
537,
24,
1532
]
],
[
[
537,
6,
6017
],
[
6017,
45,
1532
]
],
[
[
537,
18,
5415
],
[
5415,
46,
1532
]
],
[
[
537,
21,
28666
],
[
28666,
60,
1532
]
],
[
[
537,
40,
307
],
[
307,
23,
1532
]
],
[
[
537,
63,
1648
],
[
1648,
24,
1532
]
],
[
[
537,
24,
481
],
[
481,
63,
1532
]
],
[
[
537,
40,
830
],
[
830,
63,
1532
]
],
[
[
537,
74,
1376
],
[
1376,
24,
1532
]
],
[
[
537,
64,
675
],
[
675,
24,
1532
]
]
] | [
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Cyclizine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Ifosfamide"
]
],
[
[
"Cyclizine",
"{u} (Compound) downregulates {v} (Gene)",
"UBQLN2"
],
[
"UBQLN2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Ifosfamide"
]
],
[
[
"Cyclizine",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ifosfamide"
]
],
[
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ifosfamide"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
],
[
"Quazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Cyclizine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
]
] | Cyclizine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Ifosfamide (Compound)
Cyclizine (Compound) downregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Ifosfamide (Compound)
Cyclizine (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Ifosfamide (Compound)
Cyclizine (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ifosfamide
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Cyclizine (Compound) resembles Phenindamine (Compound) and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Cyclizine (Compound) resembles Diphenhydramine (Compound) and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Cyclizine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide |
DB00795 | DB08881 | 50 | 868 | [
"DDInter1725",
"DDInter1925"
] | Sulfasalazine | Vemurafenib | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulf | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. | Moderate | 1 | [
[
[
50,
24,
868
]
],
[
[
50,
6,
17404
],
[
17404,
45,
868
]
],
[
[
50,
6,
16740
],
[
16740,
46,
868
]
],
[
[
50,
7,
7273
],
[
7273,
46,
868
]
],
[
[
50,
18,
6929
],
[
6929,
57,
868
]
],
[
[
50,
24,
785
],
[
785,
63,
868
]
],
[
[
50,
63,
482
],
[
482,
24,
868
]
],
[
[
50,
24,
998
],
[
998,
24,
868
]
],
[
[
50,
64,
126
],
[
126,
24,
868
]
],
[
[
50,
25,
629
],
[
629,
24,
868
]
]
] | [
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Sulfasalazine",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Sulfasalazine",
"{u} (Compound) binds {v} (Gene)",
"SLC7A11"
],
[
"SLC7A11",
"{u} (Gene) is upregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Sulfasalazine",
"{u} (Compound) upregulates {v} (Gene)",
"GPATCH8"
],
[
"GPATCH8",
"{u} (Gene) is upregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Sulfasalazine",
"{u} (Compound) downregulates {v} (Gene)",
"ITGAE"
],
[
"ITGAE",
"{u} (Gene) is downregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
],
[
"Capmatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Sulfasalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Sulfasalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
]
] | Sulfasalazine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Vemurafenib (Compound)
Sulfasalazine (Compound) binds SLC7A11 (Gene) and SLC7A11 (Gene) is upregulated by Vemurafenib (Compound)
Sulfasalazine (Compound) upregulates GPATCH8 (Gene) and GPATCH8 (Gene) is upregulated by Vemurafenib (Compound)
Sulfasalazine (Compound) downregulates ITGAE (Gene) and ITGAE (Gene) is downregulated by Vemurafenib (Compound)
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib and Capmatinib may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Sulfasalazine may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Sulfasalazine may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib |
DB05015 | DB06636 | 1,077 | 1,623 | [
"DDInter174",
"DDInter980"
] | Belinostat | Isavuconazonium | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. Intravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle. It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma. | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and parenteral formulations. Due to low solubility in water of isavuconazole on its own, the isovuconazonium formulation is favorable as it has high solubility in water and allows for intravenous administration. This formulation also avoids the use of a cyclodextrin vehicle for solubilization required for intravenous administration of other antifungals such as voriconazole and posaconazole, eliminating concerns of nephrotoxicity associated with cyclodextrin. Isovuconazonium has excellent oral bioavailability, predictable pharmacokinetics, and a good safety profile, making it a reasonable alternative to its few other competitors on the market.[A6913,A6914,A262706] On December 08, 2023, the FDA approved the expanded use of isovuconazonium in pediatric patients for the same indications. | Moderate | 1 | [
[
[
1077,
24,
1623
]
],
[
[
1077,
24,
1250
],
[
1250,
24,
1623
]
],
[
[
1077,
24,
214
],
[
214,
63,
1623
]
],
[
[
1077,
63,
869
],
[
869,
24,
1623
]
],
[
[
1077,
25,
976
],
[
976,
63,
1623
]
],
[
[
1077,
24,
913
],
[
913,
64,
1623
]
],
[
[
1077,
24,
1250
],
[
1250,
24,
466
],
[
466,
62,
1623
]
],
[
[
1077,
24,
214
],
[
214,
63,
222
],
[
222,
23,
1623
]
],
[
[
1077,
63,
869
],
[
869,
24,
466
],
[
466,
62,
1623
]
],
[
[
1077,
63,
478
],
[
478,
23,
466
],
[
466,
62,
1623
]
]
] | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isavuconazonium"
]
]
] | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Belinostat may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Isavuconazonium
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Isavuconazonium
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Isavuconazonium
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Isavuconazonium
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Isavuconazonium |
DB00526 | DB12834 | 1,555 | 148 | [
"DDInter1355",
"DDInter1649"
] | Oxaliplatin | Secnidazole | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The | Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once it enters bacteria and parasites, secnidazole is activated by bacterial or parasitic enzymes to form a radical anion, thereby damaging and killing the target pathogen. Secnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades.[A245503, A245508] In September 2017, FDA approved secnidazole under the market name Solosec for the treatment of trichomoniasis and bacterial vaginosis. | Moderate | 1 | [
[
[
1555,
24,
148
]
],
[
[
1555,
25,
1593
],
[
1593,
24,
148
]
],
[
[
1555,
24,
1480
],
[
1480,
24,
148
]
],
[
[
1555,
63,
597
],
[
597,
24,
148
]
],
[
[
1555,
64,
1057
],
[
1057,
24,
148
]
],
[
[
1555,
24,
1330
],
[
1330,
63,
148
]
],
[
[
1555,
25,
1593
],
[
1593,
24,
1480
],
[
1480,
24,
148
]
],
[
[
1555,
24,
1480
],
[
1480,
63,
1593
],
[
1593,
24,
148
]
],
[
[
1555,
24,
1191
],
[
1191,
24,
1593
],
[
1593,
24,
148
]
],
[
[
1555,
24,
1554
],
[
1554,
25,
1593
],
[
1593,
24,
148
]
]
] | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
],
[
"Naxitamab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colchicine"
],
[
"Colchicine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
]
] | Oxaliplatin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Oxaliplatin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab and Naxitamab may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Oxaliplatin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Levodopa and Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Colchicine and Colchicine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole |
DB00193 | DB12141 | 534 | 971 | [
"DDInter1841",
"DDInter817"
] | Tramadol | Gilteritinib | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of [morphine]. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as [dul | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status. | Moderate | 1 | [
[
[
534,
24,
971
]
],
[
[
534,
23,
112
],
[
112,
23,
971
]
],
[
[
534,
24,
485
],
[
485,
24,
971
]
],
[
[
534,
1,
1100
],
[
1100,
24,
971
]
],
[
[
534,
24,
823
],
[
823,
63,
971
]
],
[
[
534,
25,
820
],
[
820,
24,
971
]
],
[
[
534,
64,
912
],
[
912,
24,
971
]
],
[
[
534,
63,
521
],
[
521,
24,
971
]
],
[
[
534,
25,
1425
],
[
1425,
25,
971
]
],
[
[
534,
25,
982
],
[
982,
64,
971
]
]
] | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Tramadol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gilteritinib"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Tramadol",
"{u} (Compound) resembles {v} (Compound)",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
]
] | Tramadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Tramadol (Compound) resembles Venlafaxine (Compound) and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Tramadol may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Tramadol may lead to a major life threatening interaction when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Tramadol may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Gilteritinib
Tramadol may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Gilteritinib |
DB00682 | DB01326 | 126 | 1,124 | [
"DDInter1951",
"DDInter312"
] | Warfarin | Cefamandole | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, [cefamandole nafate]. It is no longer marketed in the United States. | Moderate | 1 | [
[
[
126,
24,
1124
]
],
[
[
126,
24,
1305
],
[
1305,
1,
1124
]
],
[
[
126,
24,
665
],
[
665,
40,
1124
]
],
[
[
126,
63,
164
],
[
164,
40,
1124
]
],
[
[
126,
63,
277
],
[
277,
1,
1124
]
],
[
[
126,
63,
597
],
[
597,
24,
1124
]
],
[
[
126,
24,
361
],
[
361,
24,
1124
]
],
[
[
126,
24,
1305
],
[
1305,
1,
665
],
[
665,
40,
1124
]
],
[
[
126,
24,
665
],
[
665,
40,
1305
],
[
1305,
1,
1124
]
],
[
[
126,
63,
164
],
[
164,
40,
1305
],
[
1305,
1,
1124
]
]
] | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefamandole"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefaclor"
],
[
"Cefaclor",
"{u} (Compound) resembles {v} (Compound)",
"Cefamandole"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefamandole"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefalotin"
],
[
"Cefalotin",
"{u} (Compound) resembles {v} (Compound)",
"Cefamandole"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefmetazole"
],
[
"Cefmetazole",
"{u} (Compound) resembles {v} (Compound)",
"Cefamandole"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefamandole"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefamandole"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefaclor"
],
[
"Cefaclor",
"{u} (Compound) resembles {v} (Compound)",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefamandole"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefaclor"
],
[
"Cefaclor",
"{u} (Compound) resembles {v} (Compound)",
"Cefamandole"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefalotin"
],
[
"Cefalotin",
"{u} (Compound) resembles {v} (Compound)",
"Cefaclor"
],
[
"Cefaclor",
"{u} (Compound) resembles {v} (Compound)",
"Cefamandole"
]
]
] | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefaclor and Cefaclor (Compound) resembles Cefamandole (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefamandole (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefalotin and Cefalotin (Compound) resembles Cefamandole (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefmetazole and Cefmetazole (Compound) resembles Cefamandole (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cefamandole
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefamandole
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefaclor and Cefaclor (Compound) resembles Cefuroxime (Compound) and Cefuroxime (Compound) resembles Cefamandole (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefaclor (Compound) and Cefaclor (Compound) resembles Cefamandole (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefalotin and Cefalotin (Compound) resembles Cefaclor (Compound) and Cefaclor (Compound) resembles Cefamandole (Compound) |
DB06372 | DB09054 | 259 | 384 | [
"DDInter1594",
"DDInter905"
] | Rilonacept | Idelalisib | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability. | Moderate | 1 | [
[
[
259,
24,
384
]
],
[
[
259,
25,
725
],
[
725,
63,
384
]
],
[
[
259,
63,
328
],
[
328,
24,
384
]
],
[
[
259,
24,
287
],
[
287,
63,
384
]
],
[
[
259,
24,
1468
],
[
1468,
24,
384
]
],
[
[
259,
64,
980
],
[
980,
24,
384
]
],
[
[
259,
25,
1259
],
[
1259,
64,
384
]
],
[
[
259,
24,
405
],
[
405,
64,
384
]
],
[
[
259,
63,
134
],
[
134,
25,
384
]
],
[
[
259,
24,
594
],
[
594,
25,
384
]
]
] | [
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Rilonacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Satralizumab"
],
[
"Satralizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
],
[
"Diroximel fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Rilonacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
],
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Rilonacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
]
] | Rilonacept may lead to a major life threatening interaction when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Rilonacept may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Rilonacept may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Idelalisib
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib and Acalabrutinib may lead to a major life threatening interaction when taken with Idelalisib
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may lead to a major life threatening interaction when taken with Idelalisib
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Idelalisib |
DB00976 | DB12245 | 1,056 | 823 | [
"DDInter1758",
"DDInter1863"
] | Telithromycin | Triclabendazole | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections. | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola gigantica_, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452] | Moderate | 1 | [
[
[
1056,
24,
823
]
],
[
[
1056,
62,
112
],
[
112,
23,
823
]
],
[
[
1056,
63,
1010
],
[
1010,
24,
823
]
],
[
[
1056,
24,
28
],
[
28,
24,
823
]
],
[
[
1056,
64,
543
],
[
543,
24,
823
]
],
[
[
1056,
25,
971
],
[
971,
24,
823
]
],
[
[
1056,
24,
1619
],
[
1619,
63,
823
]
],
[
[
1056,
35,
609
],
[
609,
24,
823
]
],
[
[
1056,
1,
1570
],
[
1570,
24,
823
]
],
[
[
1056,
25,
868
],
[
868,
25,
823
]
]
] | [
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Telithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triclabendazole"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Telithromycin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Telithromycin",
"{u} (Compound) resembles {v} (Compound)",
"Azithromycin"
],
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
]
] | Telithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Telithromycin may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Telithromycin may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Telithromycin (Compound) resembles Clarithromycin (Compound) and Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Telithromycin (Compound) resembles Azithromycin (Compound) and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Telithromycin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Triclabendazole |
DB06626 | DB08899 | 263 | 129 | [
"DDInter147",
"DDInter649"
] | Axitinib | Enzalutamide | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors. Axitinib is an indazole derivative. It is most commonly marketed under the name Inlyta® and is available in oral formulations. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly. | Major | 2 | [
[
[
263,
25,
129
]
],
[
[
263,
63,
918
],
[
918,
1,
129
]
],
[
[
263,
25,
1510
],
[
1510,
24,
129
]
],
[
[
263,
64,
851
],
[
851,
24,
129
]
],
[
[
263,
63,
529
],
[
529,
24,
129
]
],
[
[
263,
24,
242
],
[
242,
63,
129
]
],
[
[
263,
25,
1040
],
[
1040,
63,
129
]
],
[
[
263,
23,
286
],
[
286,
63,
129
]
],
[
[
263,
62,
837
],
[
837,
24,
129
]
],
[
[
263,
24,
875
],
[
875,
24,
129
]
]
] | [
[
[
"Axitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} (Compound) resembles {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Axitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Axitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Axitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Axitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Axitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
],
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
]
] | Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Axitinib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Axitinib may lead to a major life threatening interaction when taken with Nefazodone and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Axitinib may lead to a major life threatening interaction when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Axitinib may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Axitinib may cause a minor interaction that can limit clinical effects when taken with Pantoprazole and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide |
DB00220 | DB06655 | 798 | 5 | [
"DDInter1276",
"DDInter1077"
] | Nelfinavir | Liraglutide | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide was granted FDA approval on January 25, 2010. | Moderate | 1 | [
[
[
798,
24,
5
]
],
[
[
798,
24,
353
],
[
353,
23,
5
]
],
[
[
798,
24,
1142
],
[
1142,
24,
5
]
],
[
[
798,
63,
176
],
[
176,
24,
5
]
],
[
[
798,
25,
1491
],
[
1491,
24,
5
]
],
[
[
798,
25,
1019
],
[
1019,
63,
5
]
],
[
[
798,
24,
1296
],
[
1296,
63,
5
]
],
[
[
798,
23,
222
],
[
222,
24,
5
]
],
[
[
798,
40,
1327
],
[
1327,
24,
5
]
],
[
[
798,
1,
215
],
[
215,
24,
5
]
]
] | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
[
"Griseofulvin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liraglutide"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
],
[
"Orlistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Nelfinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Nelfinavir",
"{u} (Compound) resembles {v} (Compound)",
"Saquinavir"
],
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Nelfinavir",
"{u} (Compound) resembles {v} (Compound)",
"Indinavir"
],
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
]
] | Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Orlistat and Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Nelfinavir may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Nelfinavir may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Nelfinavir (Compound) resembles Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Nelfinavir (Compound) resembles Indinavir (Compound) and Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide |
DB01320 | DB04845 | 651 | 309 | [
"DDInter783",
"DDInter1001"
] | Fosphenytoin | Ixabepilone | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials. | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation. | Moderate | 1 | [
[
[
651,
24,
309
]
],
[
[
651,
6,
8374
],
[
8374,
45,
309
]
],
[
[
651,
21,
28736
],
[
28736,
60,
309
]
],
[
[
651,
63,
60
],
[
60,
23,
309
]
],
[
[
651,
40,
307
],
[
307,
23,
309
]
],
[
[
651,
64,
1419
],
[
1419,
24,
309
]
],
[
[
651,
24,
1619
],
[
1619,
63,
309
]
],
[
[
651,
25,
1593
],
[
1593,
63,
309
]
],
[
[
651,
24,
1487
],
[
1487,
24,
309
]
],
[
[
651,
63,
1220
],
[
1220,
24,
309
]
]
] | [
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ixabepilone"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) causes {v} (Side Effect)",
"Dehydration"
],
[
"Dehydration",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ixabepilone"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
],
[
"Capecitabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ixabepilone"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ixabepilone"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
]
] | Fosphenytoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Fosphenytoin (Compound) causes Dehydration (Side Effect) and Dehydration (Side Effect) is caused by Ixabepilone (Compound)
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine may cause a minor interaction that can limit clinical effects when taken with Ixabepilone
Fosphenytoin (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ixabepilone
Fosphenytoin may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Fosphenytoin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone |
DB00347 | DB00405 | 917 | 128 | [
"DDInter1871",
"DDInter517"
] | Trimethadione | Dexbrompheniramine | An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378) | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Moderate | 1 | [
[
[
917,
24,
128
]
],
[
[
917,
24,
662
],
[
662,
63,
128
]
],
[
[
917,
63,
475
],
[
475,
24,
128
]
],
[
[
917,
24,
1594
],
[
1594,
35,
128
]
],
[
[
917,
24,
662
],
[
662,
35,
1376
],
[
1376,
63,
128
]
],
[
[
917,
24,
1376
],
[
1376,
74,
662
],
[
662,
63,
128
]
],
[
[
917,
24,
222
],
[
222,
63,
662
],
[
662,
63,
128
]
],
[
[
917,
24,
13
],
[
13,
24,
662
],
[
662,
63,
128
]
],
[
[
917,
63,
475
],
[
475,
24,
662
],
[
662,
63,
128
]
],
[
[
917,
5,
11624
],
[
11624,
44,
1435
],
[
1435,
63,
128
]
]
] | [
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Trimethadione",
"{u} (Compound) treats {v} (Disease)",
"epilepsy syndrome"
],
[
"epilepsy syndrome",
"{u} (Disease) is treated by {v} (Compound)",
"Levetiracetam"
],
[
"Levetiracetam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
]
] | Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Dexbrompheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Diphenhydramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Carbinoxamine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Trimethadione (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Levetiracetam (Compound) and Levetiracetam may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine |
DB00308 | DB01177 | 347 | 77 | [
"DDInter901",
"DDInter904"
] | Ibutilide | Idarubicin | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Major | 2 | [
[
[
347,
25,
77
]
],
[
[
347,
21,
29170
],
[
29170,
60,
77
]
],
[
[
347,
23,
112
],
[
112,
23,
77
]
],
[
[
347,
25,
823
],
[
823,
63,
77
]
],
[
[
347,
24,
543
],
[
543,
24,
77
]
],
[
[
347,
25,
918
],
[
918,
24,
77
]
],
[
[
347,
64,
618
],
[
618,
24,
77
]
],
[
[
347,
24,
659
],
[
659,
63,
77
]
],
[
[
347,
25,
351
],
[
351,
64,
77
]
],
[
[
347,
24,
976
],
[
976,
64,
77
]
]
] | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
]
],
[
[
"Ibutilide",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac failure congestive"
],
[
"Cardiac failure congestive",
"{u} (Side Effect) is caused by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Ibutilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idarubicin"
]
],
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Ibutilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abarelix"
],
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Ibutilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
]
],
[
[
"Ibutilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
]
]
] | Ibutilide (Compound) causes Cardiac failure congestive (Side Effect) and Cardiac failure congestive (Side Effect) is caused by Idarubicin (Compound)
Ibutilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Ibutilide may lead to a major life threatening interaction when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Ibutilide may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Ibutilide may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Ibutilide may lead to a major life threatening interaction when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Ibutilide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Ibutilide may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Idarubicin
Ibutilide may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Idarubicin |
DB00277 | DB00938 | 1,031 | 455 | [
"DDInter1791",
"DDInter1635"
] | Theophylline | Salmeterol | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD. | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994. | Moderate | 1 | [
[
[
1031,
24,
455
]
],
[
[
1031,
25,
1523
],
[
1523,
25,
455
]
],
[
[
1031,
24,
688
],
[
688,
63,
455
]
],
[
[
1031,
5,
11649
],
[
11649,
44,
455
]
],
[
[
1031,
6,
8374
],
[
8374,
45,
455
]
],
[
[
1031,
21,
28722
],
[
28722,
60,
455
]
],
[
[
1031,
24,
167
],
[
167,
23,
455
]
],
[
[
1031,
24,
708
],
[
708,
62,
455
]
],
[
[
1031,
25,
1121
],
[
1121,
24,
455
]
],
[
[
1031,
63,
600
],
[
600,
24,
455
]
]
] | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Theophylline",
"{u} (Compound) treats {v} (Disease)",
"asthma"
],
[
"asthma",
"{u} (Disease) is treated by {v} (Compound)",
"Salmeterol"
]
],
[
[
"Theophylline",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Salmeterol"
]
],
[
[
"Theophylline",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Salmeterol"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salmeterol"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salmeterol"
]
],
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bisoprolol"
],
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
]
] | Theophylline may lead to a major life threatening interaction when taken with Labetalol and Labetalol may lead to a major life threatening interaction when taken with Salmeterol
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Theophylline (Compound) treats asthma (Disease) and asthma (Disease) is treated by Salmeterol (Compound)
Theophylline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salmeterol (Compound)
Theophylline (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Salmeterol (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Salmeterol
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a minor interaction that can limit clinical effects when taken with Salmeterol
Theophylline may lead to a major life threatening interaction when taken with Bisoprolol and Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol |
DB00816 | DB01576 | 1,674 | 93 | [
"DDInter1346",
"DDInter526"
] | Orciprenaline | Dextroamphetamine | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Dextroamphetamine is the dextrorotatory enantiomer of amphetamine. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label]. | Moderate | 1 | [
[
[
1674,
24,
93
]
],
[
[
1674,
63,
73
],
[
73,
1,
93
]
],
[
[
1674,
63,
80
],
[
80,
40,
93
]
],
[
[
1674,
24,
1529
],
[
1529,
40,
93
]
],
[
[
1674,
24,
22
],
[
22,
24,
93
]
],
[
[
1674,
21,
28809
],
[
28809,
60,
93
]
],
[
[
1674,
63,
1636
],
[
1636,
24,
93
]
],
[
[
1674,
35,
1148
],
[
1148,
24,
93
]
],
[
[
1674,
24,
659
],
[
659,
63,
93
]
],
[
[
1674,
24,
1629
],
[
1629,
64,
93
]
]
] | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextroamphetamine"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} (Compound) resembles {v} (Compound)",
"Dextroamphetamine"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphetamine"
],
[
"Amphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Dextroamphetamine"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
[
"Metamfetamine",
"{u} (Compound) resembles {v} (Compound)",
"Dextroamphetamine"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextroamphetamine"
]
],
[
[
"Orciprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dextroamphetamine"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextroamphetamine"
]
],
[
[
"Orciprenaline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextroamphetamine"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextroamphetamine"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextroamphetamine"
]
]
] | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine (Compound) resembles Dextroamphetamine (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Dextroamphetamine (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles Dextroamphetamine (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Dextroamphetamine
Orciprenaline (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Dextroamphetamine (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Dextroamphetamine
Orciprenaline (Compound) resembles Isoprenaline (Compound) and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Dextroamphetamine
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Dextroamphetamine
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Dextroamphetamine |
DB00802 | DB01168 | 1,322 | 1,053 | [
"DDInter43",
"DDInter1526"
] | Alfentanil | Procarbazine | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
1322,
25,
1053
]
],
[
[
1322,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
1322,
24,
100
],
[
100,
24,
1053
]
],
[
[
1322,
24,
830
],
[
830,
63,
1053
]
],
[
[
1322,
63,
1648
],
[
1648,
24,
1053
]
],
[
[
1322,
63,
73
],
[
73,
25,
1053
]
],
[
[
1322,
24,
1259
],
[
1259,
64,
1053
]
],
[
[
1322,
25,
1039
],
[
1039,
64,
1053
]
],
[
[
1322,
64,
1494
],
[
1494,
25,
1053
]
],
[
[
1322,
25,
222
],
[
222,
25,
1053
]
]
] | [
[
[
"Alfentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Alfentanil",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Procarbazine"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Alfentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Alfentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Alfentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
]
] | Alfentanil (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Procarbazine
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Procarbazine
Alfentanil may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Procarbazine
Alfentanil may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may lead to a major life threatening interaction when taken with Procarbazine
Alfentanil may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Procarbazine |
DB04868 | DB06717 | 478 | 875 | [
"DDInter1293",
"DDInter778"
] | Nilotinib | Fosaprepitant | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML. | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
478,
24,
875
]
],
[
[
478,
63,
723
],
[
723,
1,
875
]
],
[
[
478,
21,
29180
],
[
29180,
60,
875
]
],
[
[
478,
63,
222
],
[
222,
23,
875
]
],
[
[
478,
23,
466
],
[
466,
62,
875
]
],
[
[
478,
64,
1101
],
[
1101,
23,
875
]
],
[
[
478,
25,
760
],
[
760,
63,
875
]
],
[
[
478,
63,
86
],
[
86,
24,
875
]
],
[
[
478,
24,
761
],
[
761,
24,
875
]
],
[
[
478,
24,
214
],
[
214,
63,
875
]
]
] | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} (Compound) resembles {v} (Compound)",
"Fosaprepitant"
]
],
[
[
"Nilotinib",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal distension"
],
[
"Abdominal distension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fosaprepitant"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
]
] | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Nilotinib (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Fosaprepitant (Compound)
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Fosaprepitant
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fosaprepitant
Nilotinib may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Fosaprepitant
Nilotinib may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant |
DB00468 | DB01072 | 1,424 | 915 | [
"DDInter1557",
"DDInter129"
] | Quinine | Atazanavir | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. | Moderate | 1 | [
[
[
1424,
24,
915
]
],
[
[
1424,
25,
1327
],
[
1327,
1,
915
]
],
[
[
1424,
6,
4973
],
[
4973,
45,
915
]
],
[
[
1424,
21,
28642
],
[
28642,
60,
915
]
],
[
[
1424,
24,
1374
],
[
1374,
62,
915
]
],
[
[
1424,
63,
1031
],
[
1031,
23,
915
]
],
[
[
1424,
63,
1101
],
[
1101,
24,
915
]
],
[
[
1424,
24,
129
],
[
129,
63,
915
]
],
[
[
1424,
25,
1011
],
[
1011,
63,
915
]
],
[
[
1424,
24,
770
],
[
770,
24,
915
]
]
] | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} (Compound) resembles {v} (Compound)",
"Atazanavir"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Atazanavir"
]
],
[
[
"Quinine",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Atazanavir"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Atazanavir"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Atazanavir"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
]
] | Quinine may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir (Compound) resembles Atazanavir (Compound)
Quinine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Atazanavir (Compound)
Quinine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Atazanavir (Compound)
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Atazanavir
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Atazanavir
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir
Quinine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir |
DB00490 | DB09280 | 946 | 1,604 | [
"DDInter254",
"DDInter1101"
] | Buspirone | Lumacaftor | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs. Unlike many drugs used to treat anxiety, buspirone does not exhibit anticonvulsant, sedative, hypnotic, and muscle-relaxant properties. Due to these characteristics, buspirone been termed 'anxioselective'. First synthesized in 1968 then patented in 1975, it is commonly marketed under the brand name Buspar®. Buspirone was first approved in 1986 by the FDA and has been used to treat anxiety disorders, such as generalized anxiety disorder (GAD), and relieve symptoms of anxiety | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a transmembrane ion channel involved in the transport of chloride and sodium ions across cell membranes of the lungs, pancreas, and other organs. Mutations in the CFTR gene result in altered production, misfolding, or function of the CFTR protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to infections, lung damage, pancreatic insufficiency, and malnutrition. Lumacaftor improves CF symptoms and underlying disease pathology by aiding the conformational stability of F508del-mutated CFTR proteins, preventing misfolding and resulting in increased processing and trafficking of mature protein to the cell surface. Results from clinical trials indicated that treatment with Orkambi (lumacaftor/ivacaftor) results in improved lung function, reduced chance of experiencing a pulmonary exacerbation, increased weight gain, and improvements in CF symptoms.[FDA Label] This data has been heavily scrutinized, however, with clinical trials showing only modest improvements despite a hefty yearly cost of $259,000 for Orkambi. Improvements in lung function (ppFEV1) were found to be statistically significant, but minimal, with only a 2.6-3.0% change from baseline with more than 70% of patients failing to achieve an absolute improvement of at least 5%.[A20343, L936] A wide variety of CFTR mutations correlate to the Cystic Fibrosis phenotype and are associated with differing levels of disease severity. The most common mutation, affecting approximately 70% of patients with CF worldwide, is known as F508del-CFTR, or delta-F508 (ΔF508), in which a deletion in the amino acid phenylalanine at position 508 results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes. When used in combination with as the fixed dose combination product Orkambi, lumacaftor is specific for the management of CF in patients with delta-F508 mutations as it acts as a protein-folding chaperone, aiding the conformational stability of the mutated CFTR protein. Consequently, lumacaftor increases successful production of CFTR ion channels and the total number of receptors available for use at the cell membrane for fluid and ion transport. The next most common mutation, G551D, affecting 4-5% of CF patients worldwide, is characterized as a missense mutation, whereby there is sufficient amount of protein at the cell surface, but opening and closing mechanisms of the channel are altered. Treatment of patients with G551D and other rarer missense mutations is usually managed with (Kalydeco), as it aids with altered gating mechanisms by potentiating channel opening probability of CFTR protein. Prior to the development of lumacaftor and (Kalydeco), management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process. Approved for use by the Food and Drug Administration in July 2015 and by Health Canada in January 2016, Orkambi was the first combination product approved for the management of Cystic Fibrosis with delta-F508 mutations. Ivacaftor is manufactured and distributed by Vertex Pharmaceuticals. | Major | 2 | [
[
[
946,
25,
1604
]
],
[
[
946,
24,
629
],
[
629,
25,
1604
]
],
[
[
946,
24,
159
],
[
159,
64,
1604
]
],
[
[
946,
24,
629
],
[
629,
64,
1171
],
[
1171,
24,
1604
]
],
[
[
946,
24,
159
],
[
159,
63,
1171
],
[
1171,
24,
1604
]
],
[
[
946,
24,
478
],
[
478,
24,
573
],
[
573,
24,
1604
]
],
[
[
946,
25,
129
],
[
129,
23,
1060
],
[
1060,
62,
1604
]
],
[
[
946,
25,
129
],
[
129,
63,
1171
],
[
1171,
24,
1604
]
],
[
[
946,
63,
600
],
[
600,
24,
1060
],
[
1060,
62,
1604
]
],
[
[
946,
24,
723
],
[
723,
24,
1060
],
[
1060,
62,
1604
]
]
] | [
[
[
"Buspirone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meloxicam"
],
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
],
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
],
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Buspirone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enfortumab vedotin"
],
[
"Enfortumab vedotin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lumacaftor"
]
],
[
[
"Buspirone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
],
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],
[
"Enfortumab vedotin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lumacaftor"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],
[
"Enfortumab vedotin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lumacaftor"
]
]
] | Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Lumacaftor
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may lead to a major life threatening interaction when taken with Lumacaftor
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Meloxicam and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine and Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Buspirone may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin and Enfortumab vedotin may cause a minor interaction that can limit clinical effects when taken with Lumacaftor
Buspirone may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a minor interaction that can limit clinical effects when taken with Lumacaftor
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a minor interaction that can limit clinical effects when taken with Lumacaftor |
DB00747 | DB00909 | 1,442 | 306 | [
"DDInter1647",
"DDInter1971"
] | Scopolamine | Zonisamide | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants. As an acetylcholine analogue, scopolamine can antagonize muscarinic acetylcholine receptors (mAChRs) in the central nervous system and throughout the body, inducing several therapeutic and adverse effects related to alteration of parasympathetic nervous system and cholinergic signalling.[A228758, L31578] Due to its dose-dependent adverse effects, scopolamine was the first drug to be offered commercially as a transdermal delivery system, Scopoderm TTS®, in 1981.[A228423, | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate.[L42530,L42535] Zonisamide represents an alternative for patients that remain refractory to established antiepileptic drugs. In 1989, it was approved for commercial use in Japan. The US and Europe approved it in 2000 and 2005, respectively.[A1379,A1383] | Major | 2 | [
[
[
1442,
25,
306
]
],
[
[
1442,
21,
28691
],
[
28691,
60,
306
]
],
[
[
1442,
24,
407
],
[
407,
63,
306
]
],
[
[
1442,
63,
475
],
[
475,
24,
306
]
],
[
[
1442,
24,
537
],
[
537,
64,
306
]
],
[
[
1442,
63,
1594
],
[
1594,
25,
306
]
],
[
[
1442,
74,
85
],
[
85,
25,
306
]
],
[
[
1442,
24,
1507
],
[
1507,
25,
306
]
],
[
[
1442,
21,
28691
],
[
28691,
60,
609
],
[
609,
63,
306
]
],
[
[
1442,
21,
29054
],
[
29054,
60,
530
],
[
530,
24,
306
]
]
] | [
[
[
"Scopolamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
]
],
[
[
"Scopolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is caused by {v} (Compound)",
"Zonisamide"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zonisamide"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zonisamide"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
]
],
[
[
"Scopolamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
[
"Dicyclomine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
]
],
[
[
"Scopolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zonisamide"
]
],
[
[
"Scopolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Speech disorder"
],
[
"Speech disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zonisamide"
]
]
] | Scopolamine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Zonisamide (Compound)
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may lead to a major life threatening interaction when taken with Zonisamide
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may lead to a major life threatening interaction when taken with Zonisamide
Scopolamine (Compound) resembles Atropine (Compound) and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may lead to a major life threatening interaction when taken with Zonisamide
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may lead to a major life threatening interaction when taken with Zonisamide
Scopolamine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Clarithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide
Scopolamine (Compound) causes Speech disorder (Side Effect) and Speech disorder (Side Effect) is caused by Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide |
DB00163 | DB00515 | 1,461 | 589 | [
"DDInter1943",
"DDInter387"
] | Vitamin E | Cisplatin | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are currently being researched for use in the treatment of diseases causing bone loss, cardiovascular diseases, diabetes mellitus and associated comorbidities, eye diseases, inflammatory diseases (including skin conditions), lipid disorders, neurological diseases, and radiation damage. Though this research is so far inconclusive, vitamin E remains a popular supplement and is generally considered safe by the FDA[FDA Label]. | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin. | Moderate | 1 | [
[
[
1461,
24,
589
]
],
[
[
1461,
6,
2490
],
[
2490,
45,
589
]
],
[
[
1461,
62,
58
],
[
58,
24,
589
]
],
[
[
1461,
24,
168
],
[
168,
24,
589
]
],
[
[
1461,
24,
77
],
[
77,
63,
589
]
],
[
[
1461,
23,
251
],
[
251,
24,
589
]
],
[
[
1461,
23,
167
],
[
167,
63,
589
]
],
[
[
1461,
24,
1064
],
[
1064,
25,
589
]
],
[
[
1461,
24,
869
],
[
869,
64,
589
]
],
[
[
1461,
62,
1066
],
[
1066,
25,
589
]
]
] | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Vitamin E",
"{u} (Compound) binds {v} (Gene)",
"NQO1"
],
[
"NQO1",
"{u} (Gene) is bound by {v} (Compound)",
"Cisplatin"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
]
]
] | Vitamin E (Compound) binds NQO1 (Gene) and NQO1 (Gene) is bound by Cisplatin (Compound)
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Cisplatin
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may lead to a major life threatening interaction when taken with Cisplatin
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Cisplatin |
DB11986 | DB14723 | 484 | 159 | [
"DDInter648",
"DDInter1026"
] | Entrectinib | Larotrectinib | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA. | Moderate | 1 | [
[
[
484,
24,
159
]
],
[
[
484,
62,
222
],
[
222,
23,
159
]
],
[
[
484,
23,
907
],
[
907,
23,
159
]
],
[
[
484,
63,
479
],
[
479,
23,
159
]
],
[
[
484,
64,
318
],
[
318,
23,
159
]
],
[
[
484,
25,
1375
],
[
1375,
24,
159
]
],
[
[
484,
63,
63
],
[
63,
24,
159
]
],
[
[
484,
64,
78
],
[
78,
24,
159
]
],
[
[
484,
24,
1412
],
[
1412,
63,
159
]
],
[
[
484,
24,
1619
],
[
1619,
24,
159
]
]
] | [
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Entrectinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
],
[
[
"Entrectinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
],
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
],
[
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
],
[
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
],
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
],
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
],
[
"Calaspargase pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
]
] | Entrectinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Entrectinib may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Entrectinib may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Entrectinib may lead to a major life threatening interaction when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Entrectinib may lead to a major life threatening interaction when taken with Droperidol and Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib |
DB00241 | DB00341 | 288 | 1,242 | [
"DDInter257",
"DDInter343"
] | Butalbital | Cetirizine | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervous system (CNS) depression that ranges from mild sedation to general anesthesia. Butalbital has a low degree of selectivity and a narrow therapeutic index. Typically indicated to manage tension (or muscle contraction) headaches, butalbital is often combined with one or more therapeutic agents, such as acetylsalicylic acid, acetaminophen, aspirin, and caffeine. There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines thus it is not indicated for such condition. As with other barbiturates | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms , . One of the most common uses for this drug is for a condition called _allergic rhinitis_. The prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. Allergic rhinitis is associated with multiple missed or unproductive days at work and school, problems with sleep, and other difficulties with day to day activities for many individuals . Furthermore, some antihistamine agents that are used to treat this condition cause undesirable, sedating effects . Cetirizine is one of the first second-generation H1 antihistamines (SGAHs) formulated to selectively inhibit the H1 receptor without sedating effects . | Moderate | 1 | [
[
[
288,
24,
1242
]
],
[
[
288,
24,
1031
],
[
1031,
23,
1242
]
],
[
[
288,
25,
475
],
[
475,
24,
1242
]
],
[
[
288,
24,
1614
],
[
1614,
63,
1242
]
],
[
[
288,
40,
1023
],
[
1023,
24,
1242
]
],
[
[
288,
63,
1648
],
[
1648,
24,
1242
]
],
[
[
288,
1,
536
],
[
536,
63,
1242
]
],
[
[
288,
24,
701
],
[
701,
35,
1242
]
],
[
[
288,
24,
1031
],
[
1031,
24,
851
],
[
851,
63,
1242
]
],
[
[
288,
25,
475
],
[
475,
24,
537
],
[
537,
63,
1242
]
]
] | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cetirizine"
]
],
[
[
"Butalbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
],
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Butalbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
]
] | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Cetirizine
Butalbital may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Butalbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Butalbital (Compound) resembles Secobarbital (Compound) and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine (Compound) resembles Cetirizine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Butalbital may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine |
DB08816 | DB11793 | 578 | 738 | [
"DDInter1802",
"DDInter1297"
] | Ticagrelor | Niraparib | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. Niraparib was approved by the European Commission on November 16, 2017 and by Health Canada on June 27, 2019. | Moderate | 1 | [
[
[
578,
24,
738
]
],
[
[
578,
64,
1213
],
[
1213,
24,
738
]
],
[
[
578,
63,
1578
],
[
1578,
24,
738
]
],
[
[
578,
24,
1619
],
[
1619,
63,
738
]
],
[
[
578,
24,
351
],
[
351,
24,
738
]
],
[
[
578,
25,
1155
],
[
1155,
24,
738
]
],
[
[
578,
25,
913
],
[
913,
63,
738
]
],
[
[
578,
23,
1011
],
[
1011,
25,
738
]
],
[
[
578,
64,
1213
],
[
1213,
63,
1253
],
[
1253,
24,
738
]
],
[
[
578,
63,
1578
],
[
1578,
25,
1213
],
[
1213,
24,
738
]
]
] | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
],
[
"Tucatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Niraparib"
]
],
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palifermin"
],
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
]
] | Ticagrelor may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Ticagrelor may lead to a major life threatening interaction when taken with Tucatinib and Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Ticagrelor may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Niraparib
Ticagrelor may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Palifermin and Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib |
DB06616 | DB12161 | 594 | 730 | [
"DDInter224",
"DDInter512"
] | Bosutinib | Deutetrabenazine | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound . This allows less frequent dosing and a lower daily dose with improvement in tolerability . Decreased plasma fluctuations of deutetrabenazine due to attenuated metabolism may explain a lower incidence of adverse reactions associated with deutetrabenazine . Deutetrabenazine is a racemic mixture containing RR-Deutetrabenazine and SS-Deutetrabenazine [FDA Label]. Huntington's disease (HD) is a hereditary, progressive neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and neuropsychiatric disturbances that interfere with daily functioning and significantly reduce the quality of life. The most prominent physical symptom of HD that may increase the risk of injury is chorea, which is an involuntary, sudden movement that can affect any muscle and flow randomly across body regions . Psychomotor symptoms of HD, such as chorea, are related to hyperactive dopaminergic neurotransmission . Deutetrabenazine depletes the levels of presynaptic dopamine by blocking VMAT2, which is responsible for the uptake of dopamine into synaptic vesicles in monoaminergic neurons and exocytotic release . As with other agents for the treatment of neurodegenerative diseases, deutetrabenazine is a drug to alleviate the motor symptoms of HD and is not proposed to halt the progression of the disease . In clinical trials of patients with HD, 12 weeks of treatment of deutetrabenazine resulted in overall improvement in mean total maximal chorea scores and motor signs than placebo . It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets. | Moderate | 1 | [
[
[
594,
24,
730
]
],
[
[
594,
62,
112
],
[
112,
23,
730
]
],
[
[
594,
63,
1559
],
[
1559,
24,
730
]
],
[
[
594,
24,
971
],
[
971,
24,
730
]
],
[
[
594,
25,
283
],
[
283,
63,
730
]
],
[
[
594,
25,
913
],
[
913,
24,
730
]
],
[
[
594,
64,
609
],
[
609,
24,
730
]
],
[
[
594,
24,
1619
],
[
1619,
63,
730
]
],
[
[
594,
64,
11
],
[
11,
25,
730
]
],
[
[
594,
25,
877
],
[
877,
64,
730
]
]
] | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Bosutinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
]
] | Bosutinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Deutetrabenazine
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Bosutinib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Bosutinib may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Bosutinib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Bosutinib may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Deutetrabenazine
Bosutinib may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Deutetrabenazine |
DB01067 | DB01144 | 959 | 1,326 | [
"DDInter826",
"DDInter540"
] | Glipizide | Diclofenamide | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonyl | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Moderate | 1 | [
[
[
959,
24,
1326
]
],
[
[
959,
63,
504
],
[
504,
1,
1326
]
],
[
[
959,
63,
359
],
[
359,
40,
1326
]
],
[
[
959,
6,
6017
],
[
6017,
45,
1326
]
],
[
[
959,
18,
2151
],
[
2151,
57,
1326
]
],
[
[
959,
21,
28975
],
[
28975,
60,
1326
]
],
[
[
959,
24,
286
],
[
286,
63,
1326
]
],
[
[
959,
63,
688
],
[
688,
24,
1326
]
],
[
[
959,
1,
245
],
[
245,
24,
1326
]
],
[
[
959,
40,
1411
],
[
1411,
24,
1326
]
]
] | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Diclofenamide"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Diclofenamide"
]
],
[
[
"Glipizide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Diclofenamide"
]
],
[
[
"Glipizide",
"{u} (Compound) downregulates {v} (Gene)",
"CEBPB"
],
[
"CEBPB",
"{u} (Gene) is downregulated by {v} (Compound)",
"Diclofenamide"
]
],
[
[
"Glipizide",
"{u} (Compound) causes {v} (Side Effect)",
"Tension"
],
[
"Tension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Diclofenamide"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
]
],
[
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
]
],
[
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
]
]
] | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Diclofenamide (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Diclofenamide (Compound)
Glipizide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Diclofenamide (Compound)
Glipizide (Compound) downregulates CEBPB (Gene) and CEBPB (Gene) is downregulated by Diclofenamide (Compound)
Glipizide (Compound) causes Tension (Side Effect) and Tension (Side Effect) is caused by Diclofenamide (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide
Glipizide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide
Glipizide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide |
DB00845 | DB09104 | 1,490 | 286 | [
"DDInter406",
"DDInter1118"
] | Clofazimine | Magnesium hydroxide | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis treatments such as [rifampicin] and [isoniazid]. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers). | Moderate | 1 | [
[
[
1490,
24,
286
]
],
[
[
1490,
24,
820
],
[
820,
23,
286
]
],
[
[
1490,
63,
355
],
[
355,
23,
286
]
],
[
[
1490,
24,
688
],
[
688,
24,
286
]
],
[
[
1490,
25,
1593
],
[
1593,
24,
286
]
],
[
[
1490,
63,
1181
],
[
1181,
24,
286
]
],
[
[
1490,
25,
982
],
[
982,
63,
286
]
],
[
[
1490,
24,
484
],
[
484,
63,
286
]
],
[
[
1490,
64,
1166
],
[
1166,
24,
286
]
],
[
[
1490,
24,
820
],
[
820,
24,
481
],
[
481,
23,
286
]
]
] | [
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Clofazimine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Clofazimine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Clofazimine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
],
[
"Quazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
]
] | Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Clofazimine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Clofazimine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Clofazimine may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide |
DB01005 | DB10343 | 995 | 962 | [
"DDInter894",
"DDInter160"
] | Hydroxyurea | Bacillus calmette-guerin substrain tice live antigen | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the need for therapeutic monitoring, and serious side effects of secondary cancer and birth defects. | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
995,
25,
962
]
],
[
[
995,
64,
1057
],
[
1057,
25,
962
]
],
[
[
995,
24,
270
],
[
270,
64,
962
]
],
[
[
995,
63,
663
],
[
663,
25,
962
]
],
[
[
995,
24,
1488
],
[
1488,
25,
962
]
],
[
[
995,
25,
976
],
[
976,
25,
962
]
],
[
[
995,
25,
1259
],
[
1259,
64,
962
]
],
[
[
995,
64,
1057
],
[
1057,
25,
617
],
[
617,
24,
962
]
],
[
[
995,
24,
270
],
[
270,
63,
617
],
[
617,
24,
962
]
],
[
[
995,
63,
663
],
[
663,
24,
617
],
[
617,
24,
962
]
]
] | [
[
[
"Hydroxyurea",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Hydroxyurea",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[
"Fludarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Hydroxyurea",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Hydroxyurea",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Hydroxyurea",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
]
] | Hydroxyurea may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Hydroxyurea may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Hydroxyurea may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Hydroxyurea may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Bacillus calmette-guerin substrain tice live antigen
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Bacillus calmette-guerin substrain tice live antigen
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Bacillus calmette-guerin substrain tice live antigen |
DB01072 | DB08907 | 915 | 1,344 | [
"DDInter129",
"DDInter280"
] | Atazanavir | Canagliflozin | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients . | Moderate | 1 | [
[
[
915,
24,
1344
]
],
[
[
915,
24,
549
],
[
549,
1,
1344
]
],
[
[
915,
6,
4973
],
[
4973,
45,
1344
]
],
[
[
915,
21,
28873
],
[
28873,
60,
1344
]
],
[
[
915,
64,
1486
],
[
1486,
24,
1344
]
],
[
[
915,
63,
176
],
[
176,
24,
1344
]
],
[
[
915,
40,
1327
],
[
1327,
24,
1344
]
],
[
[
915,
24,
850
],
[
850,
24,
1344
]
],
[
[
915,
24,
1296
],
[
1296,
63,
1344
]
],
[
[
915,
25,
1019
],
[
1019,
63,
1344
]
]
] | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Atazanavir",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Atazanavir",
"{u} (Compound) causes {v} (Side Effect)",
"Pancreatitis"
],
[
"Pancreatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Atazanavir",
"{u} (Compound) resembles {v} (Compound)",
"Saquinavir"
],
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
]
] | Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Atazanavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Canagliflozin (Compound)
Atazanavir (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Canagliflozin (Compound)
Atazanavir may lead to a major life threatening interaction when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Atazanavir (Compound) resembles Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Atazanavir may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin |
DB01211 | DB01396 | 609 | 1,482 | [
"DDInter393",
"DDInter553"
] | Clarithromycin | Digitoxin | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | Moderate | 1 | [
[
[
609,
24,
1482
]
],
[
[
609,
64,
1252
],
[
1252,
1,
1482
]
],
[
[
609,
6,
8374
],
[
8374,
45,
1482
]
],
[
[
609,
18,
9579
],
[
9579,
46,
1482
]
],
[
[
609,
7,
17450
],
[
17450,
46,
1482
]
],
[
[
609,
18,
7247
],
[
7247,
57,
1482
]
],
[
[
609,
24,
286
],
[
286,
62,
1482
]
],
[
[
609,
62,
752
],
[
752,
23,
1482
]
],
[
[
609,
25,
976
],
[
976,
63,
1482
]
],
[
[
609,
63,
1647
],
[
1647,
24,
1482
]
]
] | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} (Compound) resembles {v} (Compound)",
"Digitoxin"
]
],
[
[
"Clarithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Digitoxin"
]
],
[
[
"Clarithromycin",
"{u} (Compound) downregulates {v} (Gene)",
"PDHX"
],
[
"PDHX",
"{u} (Gene) is upregulated by {v} (Compound)",
"Digitoxin"
]
],
[
[
"Clarithromycin",
"{u} (Compound) upregulates {v} (Gene)",
"FKBP14"
],
[
"FKBP14",
"{u} (Gene) is upregulated by {v} (Compound)",
"Digitoxin"
]
],
[
[
"Clarithromycin",
"{u} (Compound) downregulates {v} (Gene)",
"NPDC1"
],
[
"NPDC1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Digitoxin"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digitoxin"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digitoxin"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
]
]
] | Clarithromycin may lead to a major life threatening interaction when taken with Digoxin and Digoxin (Compound) resembles Digitoxin (Compound)
Clarithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Digitoxin (Compound)
Clarithromycin (Compound) downregulates PDHX (Gene) and PDHX (Gene) is upregulated by Digitoxin (Compound)
Clarithromycin (Compound) upregulates FKBP14 (Gene) and FKBP14 (Gene) is upregulated by Digitoxin (Compound)
Clarithromycin (Compound) downregulates NPDC1 (Gene) and NPDC1 (Gene) is downregulated by Digitoxin (Compound)
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Digitoxin
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Digitoxin
Clarithromycin may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin |
DB00450 | DB00748 | 78 | 662 | [
"DDInter603",
"DDInter297"
] | Droperidol | Carbinoxamine | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593) | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under 2 years of age), which can potentially cause serious health risks. | Moderate | 1 | [
[
[
78,
24,
662
]
],
[
[
78,
24,
28
],
[
28,
40,
662
]
],
[
[
78,
63,
1594
],
[
1594,
24,
662
]
],
[
[
78,
21,
28921
],
[
28921,
60,
662
]
],
[
[
78,
24,
830
],
[
830,
63,
662
]
],
[
[
78,
25,
1311
],
[
1311,
63,
662
]
],
[
[
78,
40,
1568
],
[
1568,
63,
662
]
],
[
[
78,
64,
475
],
[
475,
24,
662
]
],
[
[
78,
24,
506
],
[
506,
24,
662
]
],
[
[
78,
1,
1300
],
[
1300,
24,
662
]
]
] | [
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} (Compound) resembles {v} (Compound)",
"Carbinoxamine"
]
],
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Droperidol",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Carbinoxamine"
]
],
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Droperidol",
"{u} (Compound) resembles {v} (Compound)",
"Pimozide"
],
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Droperidol",
"{u} (Compound) resembles {v} (Compound)",
"Haloperidol"
],
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
]
] | Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl (Compound) resembles Carbinoxamine (Compound)
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Droperidol (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Carbinoxamine (Compound)
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Droperidol may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Droperidol (Compound) resembles Pimozide (Compound) and Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Droperidol may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Droperidol (Compound) resembles Haloperidol (Compound) and Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine |
DB01073 | DB01229 | 1,488 | 973 | [
"DDInter745",
"DDInter1378"
] | Fludarabine | Paclitaxel (protein-bound) | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
1488,
24,
973
]
],
[
[
1488,
24,
310
],
[
310,
63,
973
]
],
[
[
1488,
21,
28643
],
[
28643,
60,
973
]
],
[
[
1488,
23,
945
],
[
945,
23,
973
]
],
[
[
1488,
62,
1467
],
[
1467,
23,
973
]
],
[
[
1488,
23,
255
],
[
255,
62,
973
]
],
[
[
1488,
63,
134
],
[
134,
24,
973
]
],
[
[
1488,
24,
33
],
[
33,
24,
973
]
],
[
[
1488,
62,
839
],
[
839,
24,
973
]
],
[
[
1488,
25,
1011
],
[
1011,
64,
973
]
]
] | [
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Fludarabine",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Effect) is caused by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Fludarabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
]
],
[
[
"Fludarabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enoxacin"
],
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
]
],
[
[
"Fludarabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Fludarabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Fludarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paclitaxel"
]
]
] | Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Fludarabine (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Paclitaxel (Compound)
Fludarabine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Paclitaxel
Fludarabine may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Paclitaxel
Fludarabine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin and Delafloxacin may cause a minor interaction that can limit clinical effects when taken with Paclitaxel
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Fludarabine may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Fludarabine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Paclitaxel |
DB00543 | DB00938 | 87 | 455 | [
"DDInter82",
"DDInter1635"
] | Amoxapine | Salmeterol | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994. | Moderate | 1 | [
[
[
87,
24,
455
]
],
[
[
87,
24,
688
],
[
688,
63,
455
]
],
[
[
87,
7,
9650
],
[
9650,
46,
455
]
],
[
[
87,
21,
29024
],
[
29024,
60,
455
]
],
[
[
87,
25,
1593
],
[
1593,
63,
455
]
],
[
[
87,
63,
600
],
[
600,
24,
455
]
],
[
[
87,
40,
867
],
[
867,
24,
455
]
],
[
[
87,
24,
51
],
[
51,
24,
455
]
],
[
[
87,
25,
1133
],
[
1133,
24,
455
]
],
[
[
87,
1,
623
],
[
623,
63,
455
]
]
] | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Amoxapine",
"{u} (Compound) upregulates {v} (Gene)",
"HMGCS1"
],
[
"HMGCS1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Salmeterol"
]
],
[
[
"Amoxapine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypertension"
],
[
"Hypertension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Salmeterol"
]
],
[
[
"Amoxapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Amoxapine",
"{u} (Compound) resembles {v} (Compound)",
"Olanzapine"
],
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Amoxapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Amoxapine",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
]
] | Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Amoxapine (Compound) upregulates HMGCS1 (Gene) and HMGCS1 (Gene) is upregulated by Salmeterol (Compound)
Amoxapine (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Salmeterol (Compound)
Amoxapine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Amoxapine (Compound) resembles Olanzapine (Compound) and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Amoxapine may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Amoxapine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol |
DB00222 | DB09082 | 245 | 659 | [
"DDInter825",
"DDInter1934"
] | Glimepiride | Vilanterol | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456] | Moderate | 1 | [
[
[
245,
24,
659
]
],
[
[
245,
24,
1220
],
[
1220,
23,
659
]
],
[
[
245,
24,
1296
],
[
1296,
63,
659
]
],
[
[
245,
24,
88
],
[
88,
24,
659
]
],
[
[
245,
40,
959
],
[
959,
24,
659
]
],
[
[
245,
25,
839
],
[
839,
24,
659
]
],
[
[
245,
63,
176
],
[
176,
24,
659
]
],
[
[
245,
64,
600
],
[
600,
24,
659
]
],
[
[
245,
24,
772
],
[
772,
25,
659
]
],
[
[
245,
24,
1220
],
[
1220,
1,
891
],
[
891,
23,
659
]
]
] | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Glimepiride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Glimepiride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
],
[
"Carvedilol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vilanterol"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
]
]
] | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Glimepiride may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Glimepiride may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and Carvedilol may lead to a major life threatening interaction when taken with Vilanterol
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a minor interaction that can limit clinical effects when taken with Vilanterol |
DB00848 | DB04865 | 281 | 4 | [
"DDInter1044",
"DDInter1335"
] | Levamisole | Omacetaxine mepesuccinate | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this, levamisole was used as an antirheumatic therapy in the 1970s and 1980s for patients with rheumatoid arthritis. Because of its immunomodulatory effects, this drug has been studied in the treatment of various immune-mediated diseases, with some studies showing positive results. This drug has also been used in combination with other drugs for the treatment of various cancers. [A178117, A178123] Levamisole was withdrawn from the American market in 2000 due to its ability to cause serious adverse effects, including agranul | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML. | Moderate | 1 | [
[
[
281,
24,
4
]
],
[
[
281,
24,
496
],
[
496,
63,
4
]
],
[
[
281,
63,
208
],
[
208,
24,
4
]
],
[
[
281,
24,
563
],
[
563,
24,
4
]
],
[
[
281,
25,
1292
],
[
1292,
64,
4
]
],
[
[
281,
63,
126
],
[
126,
25,
4
]
],
[
[
281,
64,
1066
],
[
1066,
25,
4
]
],
[
[
281,
25,
1377
],
[
1377,
25,
4
]
],
[
[
281,
24,
496
],
[
496,
63,
1394
],
[
1394,
24,
4
]
],
[
[
281,
63,
208
],
[
208,
24,
770
],
[
770,
24,
4
]
]
] | [
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephenytoin"
],
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Levamisole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Levamisole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Levamisole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rituximab"
],
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephenytoin"
],
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
]
] | Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin and Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Levamisole may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Levamisole may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Levamisole may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Rituximab and Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin and Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate |
DB00421 | DB08907 | 443 | 1,344 | [
"DDInter1707",
"DDInter280"
] | Spironolactone | Canagliflozin | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered.[A11837, A178246] It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension. Off-label uses of spironolactone include hirsutism, female pattern hair loss, and adult acne vulgaris.[A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243, L6187] | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients . | Moderate | 1 | [
[
[
443,
24,
1344
]
],
[
[
443,
24,
549
],
[
549,
1,
1344
]
],
[
[
443,
6,
5912
],
[
5912,
45,
1344
]
],
[
[
443,
21,
28962
],
[
28962,
60,
1344
]
],
[
[
443,
24,
1486
],
[
1486,
24,
1344
]
],
[
[
443,
1,
312
],
[
312,
24,
1344
]
],
[
[
443,
24,
1019
],
[
1019,
63,
1344
]
],
[
[
443,
63,
999
],
[
999,
24,
1344
]
],
[
[
443,
40,
989
],
[
989,
24,
1344
]
],
[
[
443,
24,
549
],
[
549,
6,
16207
],
[
16207,
45,
1344
]
]
] | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Spironolactone",
"{u} (Compound) binds {v} (Gene)",
"ABCC2"
],
[
"ABCC2",
"{u} (Gene) is bound by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Spironolactone",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperkalaemia"
],
[
"Hyperkalaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Spironolactone",
"{u} (Compound) resembles {v} (Compound)",
"Eplerenone"
],
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Spironolactone",
"{u} (Compound) resembles {v} (Compound)",
"Progesterone"
],
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) binds {v} (Gene)",
"SLC5A1"
],
[
"SLC5A1",
"{u} (Gene) is bound by {v} (Compound)",
"Canagliflozin"
]
]
] | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Spironolactone (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Canagliflozin (Compound)
Spironolactone (Compound) causes Hyperkalaemia (Side Effect) and Hyperkalaemia (Side Effect) is caused by Canagliflozin (Compound)
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Spironolactone (Compound) resembles Eplerenone (Compound) and Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Spironolactone (Compound) resembles Progesterone (Compound) and Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) binds SLC5A1 (Gene) and SLC5A1 (Gene) is bound by Canagliflozin (Compound) |
DB00404 | DB00792 | 523 | 832 | [
"DDInter54",
"DDInter1878"
] | Alprazolam | Tripelennamine | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effects are generally related to the sedation it can cause. Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death. Alprazolam was given FDA approval on October 16, 1981. | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
523,
24,
832
]
],
[
[
523,
24,
100
],
[
100,
63,
832
]
],
[
[
523,
24,
649
],
[
649,
1,
832
]
],
[
[
523,
63,
1594
],
[
1594,
24,
832
]
],
[
[
523,
24,
128
],
[
128,
24,
832
]
],
[
[
523,
1,
1216
],
[
1216,
24,
832
]
],
[
[
523,
64,
475
],
[
475,
24,
832
]
],
[
[
523,
1,
686
],
[
686,
63,
832
]
],
[
[
523,
40,
1174
],
[
1174,
24,
832
]
],
[
[
523,
24,
662
],
[
662,
35,
832
]
]
] | [
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} (Compound) resembles {v} (Compound)",
"Tripelennamine"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Flurazepam"
],
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Alprazolam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Oxazepam"
],
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Temazepam"
],
[
"Temazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
]
] | Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Tripelennamine (Compound)
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Alprazolam (Compound) resembles Flurazepam (Compound) and Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Alprazolam may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Alprazolam (Compound) resembles Oxazepam (Compound) and Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Alprazolam (Compound) resembles Temazepam (Compound) and Temazepam may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Tripelennamine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine |
DB01082 | DB01413 | 1,448 | 1,403 | [
"DDInter1713",
"DDInter317"
] | Streptomycin | Cefepime | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity.[A233325,A232294] Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis. | Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics.[A2457,A249050] Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as _Pseudomonas aeruginosa_, and is also indicated for the empirical treatment of febrile neutropenia. The popularity of its third-generation predecessors, its clinical efficacy, and the high prevalence of multidrug-resistant bacteria might be some of the factors leading to an increase in the use of cefepime. The activity of cefepime against Enterobacteriaceae, _Pseudomonas aeruginosa_, and _Staphylococcus aureus_ is due to its high stability toward beta-lactamases. In general, cefepime seems to be well tolerated; however, patients treated with this antibiotic, especially those with renal impairment, may develop neurotoxicity.[A249050,L42095,L42100] | Moderate | 1 | [
[
[
1448,
24,
1403
]
],
[
[
1448,
24,
1024
],
[
1024,
40,
1403
]
],
[
[
1448,
24,
731
],
[
731,
1,
1403
]
],
[
[
1448,
63,
1087
],
[
1087,
40,
1403
]
],
[
[
1448,
63,
778
],
[
778,
1,
1403
]
],
[
[
1448,
21,
28787
],
[
28787,
60,
1403
]
],
[
[
1448,
24,
1662
],
[
1662,
63,
1403
]
],
[
[
1448,
63,
361
],
[
361,
24,
1403
]
],
[
[
1448,
35,
416
],
[
416,
24,
1403
]
],
[
[
1448,
24,
1024
],
[
1024,
40,
1462
],
[
1462,
1,
1403
]
]
] | [
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefepime"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefpodoxime"
],
[
"Cefpodoxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefepime"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftizoxime"
],
[
"Ceftizoxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefepime"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefotaxime"
],
[
"Cefotaxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefepime"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefixime"
],
[
"Cefixime",
"{u} (Compound) resembles {v} (Compound)",
"Cefepime"
]
],
[
[
"Streptomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cefepime"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefepime"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefepime"
]
],
[
[
"Streptomycin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefepime"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefpodoxime"
],
[
"Cefpodoxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefditoren"
],
[
"Cefditoren",
"{u} (Compound) resembles {v} (Compound)",
"Cefepime"
]
]
] | Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefpodoxime and Cefpodoxime (Compound) resembles Cefepime (Compound)
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Ceftizoxime and Ceftizoxime (Compound) resembles Cefepime (Compound)
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefotaxime and Cefotaxime (Compound) resembles Cefepime (Compound)
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefixime and Cefixime (Compound) resembles Cefepime (Compound)
Streptomycin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Cefepime (Compound)
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Cefepime
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefepime
Streptomycin (Compound) resembles Kanamycin (Compound) and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Cefepime
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefpodoxime and Cefpodoxime (Compound) resembles Cefditoren (Compound) and Cefditoren (Compound) resembles Cefepime (Compound) |
DB06691 | DB11823 | 849 | 858 | [
"DDInter1155",
"DDInter673"
] | Mepyramine | Esketamine | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide.[L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. Esketamine is the s-enantiomer of [Ketamine]. Ketamine is a mixture of two enantiomers (mirror image molecules). This is the first time that the FDA has approved esketamine for any use. The FDA approved ketamine (Ketalar) in 1970. Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications and therapies. The intranasal route of administration for this drug allows for easy administration and a fast onset of action, which sets it apart from many other antidepressant agents that may take several weeks to take effect. | Moderate | 1 | [
[
[
849,
24,
858
]
],
[
[
849,
63,
272
],
[
272,
24,
858
]
],
[
[
849,
74,
100
],
[
100,
24,
858
]
],
[
[
849,
24,
1609
],
[
1609,
24,
858
]
],
[
[
849,
63,
272
],
[
272,
63,
506
],
[
506,
24,
858
]
],
[
[
849,
63,
506
],
[
506,
24,
272
],
[
272,
24,
858
]
],
[
[
849,
63,
832
],
[
832,
35,
272
],
[
272,
24,
858
]
],
[
[
849,
74,
100
],
[
100,
35,
272
],
[
272,
24,
858
]
],
[
[
849,
24,
1609
],
[
1609,
63,
272
],
[
272,
24,
858
]
],
[
[
849,
74,
100
],
[
100,
63,
506
],
[
506,
24,
858
]
]
] | [
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Mepyramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Mepyramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Mepyramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
]
] | Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Mepyramine (Compound) resembles Brompheniramine (Compound) and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine (Compound) resembles Chlorpheniramine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Mepyramine (Compound) resembles Brompheniramine (Compound) and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine (Compound) resembles Chlorpheniramine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Mepyramine (Compound) resembles Brompheniramine (Compound) and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Esketamine |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.